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Patients with severe ischaemic heart disease (IHD) often undergo cardiac surgery to alleviate 
symptoms and improve survival outcomes. However, such interventions can inevitably induce 
episodes of ischaemia reperfusion (IR). IR generates large amounts of reactive oxygen species 
(ROS) which irreversibly oxidises proteins and results in cardiomyocyte death. Due to the 
heart’s inability to replenish dead cardiomyocytes, there is an imperative to investigate 
prophylactic interventions to attenuate IR injury. Our lab group previously showed that the 
novel organic CO releasing molecule, oCOm-21, preconditioned isolated rat hearts subjected 
to IR injury. From these studies it was noted that oCOm-21 produced an inotropic effect. 
Inotropy is the result of increased [Ca2+]i and Ca
2+ handling proteins which modulate [Ca2+]i 
are extremely susceptible to ROS modification. Therefore, this study aimed to 1) confirm the 
inotropic effects of oCOm-21 and 2) determine whether oCOm-21 S-nitrosylated the ryanodine 
2 receptor (RyR2) to induce inotropy. 
oCOm-21 was confirmed to be an inotrope in a concentration-dependent manner in isolated rat 
hearts. This effect was found to be dependent on a nitric oxide (NO) synthase signalling 
pathway. Attempts to further elucidate the contribution of ROS through the use of H2DCF-DA 
and NO though H2DAF-FM DA and spin trapping was performed. oCOm-21 did not alter 
H2DCF-DA or H2DAF-FM DA fluorescence. Spin trapping also failed to sensitively detect any 
cellular changes in NO due to oCOm-21 treatment. These findings suggest that low basal ROS 
and NO contribute to the inotropic and preconditioning effect seen with oCOm-21. 
RyR2 gating was examined in order to investigate the effects of oCOm-21 on myocardial 
function. oCOm-21 did not increase the number of HEK293/RyR2 cells experiencing store 
overload induced Ca2+ release (SOICR); suggesting that RyR2 release threshold was not 
altered. In isolated rat cardiomyocytes, changes in [Ca2+]i fluorescence due to oCOm-21 was 
observed but only at physiological extracellular [Ca2+]. Unfortunately, the present study could 
not detect S-nitrosylation of RyR2 due to oCOm-21 infusion through western blotting. 
Interpretation of these findings indicate that oCOm-21 may change Ca2+ reuptake or 
myofilament Ca2+ sensitivity. 
To explore the clinical relevance of oCOm-21 as an inotrope in human myocardium, oCOm-21 
was perfused onto cardiac trabeculae isolated from clinical right atrial appendage biopsies. 
oCOm-21 only exhibited an inotropic effect in patients presenting with higher body weights, 
increased body surface area, larger right atrial area and greater right atrial end systolic volume 
but lower left ventricular posterior wall thickness. This suggests that oCOm-21 can be effective 
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in the clinical setting but further evidence is needed to confirm oCOm-21’s ability to S-
nitrosylate RyR2. If so, oCOm-21 would be a novel pharmacological agent where both inotropy 
and cardioprotection are achieved through the same mechanism of action. This evidence would 
also address how a preconditioning agent may also protect against non-specific ROS damage 
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1. Introduction 
1.1 Ischaemic Heart Disease 
Ischaemic heart disease (IHD) is the single leading cause of death globally and accounts for 
17.6% of the total number of deaths in New Zealand (Ministry of Health, 2015; World Health 
Organization, 2014). Within a patient, IHD gradually develops due to the accumulation and 
deposition of fatty acids which occlude and stiffen the coronary arteries of the heart. Overtime, 
impaired coronary artery function can lead to angina, ischaemic heart damage and the formation 
of a myocardial infarct (MI). To relieve these symptoms and improve patient outcome, patients 
with severe IHD can undergo surgical interventions such as coronary artery bypass graft 
(CABG) surgery to restore blood flow through the heart tissue (Hausenloy et al., 2012). A major 
confounding factor with such surgeries is that patients are often placed under cardiopulmonary 
bypass (CPB) – a method in which a machine takes over the function of the heart and lungs to 
maintain the circulation of oxygenated blood throughout the patient (Passaroni et al., 2015). 
Alternatively, a device like the “Octopus rig” consisting of suction arms that surround the 
coronary artery, may be used to immobilise the heart and facilitate cardiac surgery though this 
procedure has been linked to cardiac damage (Scott et al., 2002; Selvanayagam et al., 2004). 
1.1.1 CPB Associated with Cardiac Surgery 
In order to initiate CPB, the aorta is cross clamped and the heart is perfused with a cardioplegic 
solution to arrest the heart in a hyperkalemic and hypothermic state. This minimises myocardial 
metabolic activity and oxygen consumption to help preserve cardiac function. However, once 
the cardiac surgery has been performed, the aortic cross clamp is released and the heart is 
rapidly and globally reperfused with blood that is anticoagulated, immunologically active (due 
to exposure in the cardiopulmonary bypass circuit) and consists of a high partial pressure of 
oxygen (Turer and Hill, 2010). Inevitably, this reintroduction of blood induces inflammation 
and ischaemia reperfusion (IR) injury which leads to cardiomyocyte death. 
1.1.2 The Contribution of CPB to Adverse Outcomes in CABG Surgery 
CABG surgery, anastomosing (joining) of a blood vessel graft to restore blood flow throughout 
the heart, significantly improves the prognosis of patients with stenosis (narrowing) of the left 
main coronary artery (Harris et al., 2013). Although mortality rates due to the procedure are 
low (2-3%), evaluation of CABG surgery question the benefits of such intervention: 1) 
echocardiographic data suggests a significant decrease in haemodynamic parameters such as 
stroke volume, ejection fraction and fractional shortening six to seven weeks postoperatively; 
2) a significant number of patients are rehospitalised following CABG surgery within six 
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months to two years of treatment (increasing from 23% to 33%, respectively) due to arrhythmia, 
angina or acute MI formation and 3) prognosis 10-12 years following CABG surgery is no more 
advantageous than pharmacological intervention (Cundiff, 2002; Geissler and Aggestrup, 2002; 
Hawkes et al., 2006; Hlatky et al., 2004; Jenkins et al., 1983; Soraas et al., 2011; Yadava et al., 
2011). This may be due to the fact that the cardioplegia performed during CPB/CABG surgery 
induces IR injury when the aortic clamp is released (Turer and Hill, 2010). The damage induced 
may also be further potentiated by the immunologically active reperfusing blood where repeated 
passages of blood through a nonendothelialised extracorpeal circuit triggers neutrophil 
activation (Levy and Tanaka, 2003; Royston, 1997). Neutrophils readily produce reactive 
oxygen species (ROS) which have been casually linked to cardiovascular dysfunction 
(Kawahito et al., 2000). It is reported that IR injury is responsible for at least 25 - 45% of 
immediate CABG surgery induced deaths (Binder et al., 2015). 
1.2 IR Injury 
1.2.1 Ischaemia 
Cardiac damage due to the cessation of blood flow occurring as a consequence of vascular 
clamping results in hypoxia, vascular dysfunction and the depletion of adenosine triphosphate 
(ATP) in the cardiac region served (Garcia-Dorado et al., 2014). Due to the lack of O2, the 
ischaemic region becomes dependent on glycolytic metabolism to generate ATP, however, this 
leads to the intracellular accumulation of lactic acid that is further increased by the build-up of 
(and inability to remove) CO2 (Piper et al., 2004). Cardiac acidosis results, leading to rapid 
inhibition of contraction which is potentiated by the sarcoplasmic endoreticulum Ca2+ ATPase 
(SERCA) being inactive due to the lack of ATP. Subsequent myocardial contractions are 
hindered due to a lack of Ca2+. Furthermore, acidosis activates the Na+/H+ exchanger (NHE) 
and in the absence of ATP, the Na+/K+ ATPase (NKA) becomes inactive resulting in a high 
cytosolic Na+ concentration (Garcia-Dorado et al., 2012). In addition to the direct damage they 
cause, these factors set the stage for reperfusion injury, the main contributor to irreversible 
cardiac damage (Piper et al., 1998) (Figure 1). 
1.2.2 Reperfusion 
To reduce ischaemic damage, blood flow must be quickly reinstated after anastomoses by 
releasing the vascular clamp. Doing so restores the cellular and mitochondrial membrane 
potential, intracellular pH and ATP synthesis (Garcia-Dorado et al., 2014). Restoration of the 
cellular membrane potential however, due to the accumulated intracellular Na+ during 
ischaemia, causes in the Na+/Ca2+ exchanger to work in reverse inducing cytosolic Ca2+ 
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overload (Piper et al., 2004). With the presence of ATP, excessive cytosolic Ca2+ is taken up 
by SERCA resulting in an increased number of activated cardiac ryanodine receptors (RyR2) 
along with the subsequent release of Ca2+. This altered myocardial Ca2+ handling leads to 
increased Ca2+ oscillations that then promote: 1) hypercontraction, excessive contractile activity 
which induces cardiomyocyte death; 2) delayed early and after depolarisations which are 
responsible for the observed arrhythmias during reperfusion; 3) the activation of degradative 
Ca2+ dependent proteases like calpain which are normally inhibited in acidic conditions and 
lead to irreversible cardiac damage and 4) the accumulation of Ca2+ in the mitochondria and 
hence the formation/opening of the mitochondrial permeability transition pore (mPTP) (Figure 
1) (Barrabes et al., 1996; Inserte et al., 2005; Priori et al., 1990; Ruiz-Meana et al., 1995). Ca2+ 
mediated opening of the mPTP results in mitochondrial swelling and rupturing that promotes 
the loss of the mitochondrial membrane potential (MMP), respiratory chain uncoupling, ATP 
synthesis arrest, ROS overproduction and the initiation of necrotic and apoptotic signalling 
pathways due to the release of mitochondrial proteins. These proteins include cytochrome c 
(cyt c) and the apoptosis-inducing factor termed small mitochondria-derived activator of 
caspases (SMAC) (Figure 1) (Baines, 2009). Mitochondrial permeabilisation also releases 
mitochondrial stored Ca2+ into the cytosol to promote additional Ca2+ oscillation inducing 
further cardiomyocyte death (Ruiz-Meana et al., 2007). 
1.2.3 Significance of ROS in IR Injury 
Although ischaemia results in the formation of ROS, reperfusion is primarily responsible for 
the damaging levels of ROS which trigger the majority of apoptosis and necrosis (Kalogeris et 
al., 2012). In basal conditions, mitochondria are the main source of cellular ROS generated 
from an electron leak at the mitochondrial electron transport chain (Becker, 2004). Leaked 
electrons can readily be transferred to O2 at complexes I and III to produce ROS such as O2
•– 
and H2O2 (Kalogeris et al., 2014). Ischaemia and reperfusion exacerbated ROS generation by 
inducing defects in the electron transport chain and providing a large influx of O2 that is readily 
able to be converted into ROS (Granger and Kvietys, 2015). Increasing ROS induces oxidative 
stress that damages mitochondrial structure and function to facilitate previously mentioned 
events, such as the release of accumulated Ca2+ in the mitochondria, the formation of the mPTP 
and the loss of the MMP (Figure 1) (Garcia-Dorado et al., 2014; Halestrap et al., 2004). 
Damaged mitochondria also exhibit impaired electron transport chain activity, decreased ATP 
synthesis and increased cyt c release (Figure 1) (Chouchani et al., 2016). In addition, the 
generated ROS can cause non-specific, irreversible protein modifications and direct damage to 
cellular membranes and proteins via lipid peroxidation or sulfhydryl bond formation (Granger 
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and Kvietys, 2015). Generated mitochondrial ROS from IR injury has been causally linked to 
impaired cardiac vasculature, disruption of excitation-contraction coupling, the generation of 
arrhythmias, cardiac remodelling, cardiac hypertrophy and fibrosis (Kalogeris et al., 2014). 
 
Figure 1. IR injury resulting in cardiomyocyte death. Hypoxia facilitated by vascular 
dysfunction during ischaemia results in the depletion of ATP and dependence on glycolytic 
metabolism resulting in H+ efflux through the Na+/H+ exchanger (NHE). This metabolic switch 
allows for the increase of the cytosolic [Na+] due to sarcoplasmic endoreticula Ca2+ ATPase 
(SERCA) and Na+/K+ ATPase (NKA) inactivity that upon reperfusion, promotes reverse mode 
activity of the Na+/Ca2+ exchanger (NCX) leading to a high cytosolic [Ca2+] and Ca2+ 
oscillations. This high cytosolic [Ca2+] is exacerbated by upregulated SERCA activity as more 
Ca2+ is released by the ryanodine 2 receptor (RyR2) in response to the higher SR [Ca2+]. 
Alternatively, reperfusion may generate reactive oxygen species (ROS) to damage 
mitochondria resulting in mitochondrial permeability pore (mPTP) formation and the release 
of cytochrome c (cyt c). These factors ultimately combine to produce cardiomyocyte death 
(adapted from Garcia-Dorado et al. 2014).  
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1.3 Conditioning 
To attenuate IR injury, the heart can be “conditioned.” Conditioning was initially defined as 
exposing the heart to multiple mild periods of ischaemia prior to a global ischaemic episode 
(Granfeldt et al., 2009). This phenomenon was first discovered by Murray et al. (1986) who 
found that clamping the left anterior descending coronary artery for four, five-minute intervals 
prior to a 90-minute episode of ischaemia in canines significantly reduced the size of the 
subsequent MI formed (Murry et al., 1986). The application of conditioning before the 
ischaemic episode is now formally known as preconditioning and, the term conditioning has 
evolved to encompass its induction during or after an ischaemic episode (known as per and 
post-conditioning, respectively). Conditioning is the most effective experimental method to 
reduce the formation of a MI while preserving cardiac function following an ischaemic episode. 
This is achieved via conditioning activating a plethora of signalling pathways that lead to an 
overall cardioprotective effect (Ferdinandy et al., 2014; Hausenloy and Yellon, 2016). 
1.3.1 Conditioning in CPB Facilitated Surgery  
In a surgical setting, conditioning is often performed via repeated clamping of a key coronary 
artery. However, in a patient with IHD, performing such a procedure provokes the risk of a 
thromboembolism (where a fatty acid plaque is dislodged and occludes a smaller coronary 
artery downstream) leading to a full blown MI (Hausenloy and Yellon, 2016). As a result, 
clinicians have begun implementing “remote conditioning” in which inducing IR injury at a 
distal skeletal muscle releases humoral triggers to produce a conditioning effect in the heart 
(Gho et al., 1996; McClanahan et al., 1993). Experimental models have shown that remote 
conditioning using an inflatable blood pressure cuff at a peripheral limb mimics the 
conditioning effect via clamping of the left anterior descending coronary artery (Przyklenk et 
al., 1993). In patients, remote conditioning is achieved through multiple cycles of inflation and 
deflation of a blood pressure cuff at the brachial artery (Hausenloy et al., 2015). 
Initial studies involving remote conditioning in patients seemed contradictory where remote 
conditioning with CABG surgery produced beneficial outcomes (reduced troponin I and 
creatinine kinase) while those undergoing aortic valve replacement surgery exhibited no 
significant protective effects. More recent and sufficiently powered randomised sham-
controlled trials have found no clinical benefit with remote conditioning (RIPValve trial) 
(Hausenloy et al., 2015; Meybohm et al., 2015; Pinaud et al., 2016; Sivaraman et al., 2015). In 
the ERICCA trial where patients were undergoing CABG surgery with or without valvular 
surgery, remote conditioning did not improve clinical outcomes. In fact, the number of deaths 
6 
due to cardiac complications in the remote conditioning group was no different compared to 
the sham control treatment group (p = 0.08) (Hausenloy et al., 2015). Findings from the 
RIPHeart study where remote conditioning was performed in only patients requiring CABG 
surgery reported similar findings (Meybohm et al., 2015). These studies therefore question the 
safety and efficacy of remote conditioning. It is known that the dislodging of plaques due to 
remote conditioning go on to trigger pro-inflammatory pathways leading to thrombosis and the 
progression of atherosclerosis. Remote ischaemic conditioning is associated with increased 
expression of pro-inflammatory tumour necrosis signalling and myeloperoxidase activity while 
CPB activates neutrophils (marked by the loss of L-selectin and upregulation of CD11b/CD18) 
to generate ROS and induces IR injury which all compromise cardiac function (Albrecht et al., 
2013; Kawahito et al., 2000; Lucchinetti et al., 2012). These outcomes highlight the clinical 
need to investigate alternative, non-invasive methods to induce a conditioning effect to improve 
the outcome of patients undergoing cardiac surgery. 
1.4 Carbon Monoxide 
Carbon monoxide (CO) is a gaseous signalling molecule linked to anti-inflammatory, anti-
apoptotic and vasodilatory effects (Bannenberg and Vieira, 2009; Motterlini and Otterbein, 
2010). CO is endogenously produced as a by-product of haem catabolism by inducible haem 
oxygenase (HO) -1 (HO-1) or constitutive HO-2. Both HO-1 and 2 expression is upregulated 
in conditions such as oxidative stress, hypoxia and hypothermia (Otterbein and Choi, 2000). 
Several studies examining the inhibition or deficiency of HO-1 in cells, mice, rats and humans 
have shown that the CO produced acts as a ubiquitous second messenger signalling molecule 
to induce these mentioned effects (Bilban et al., 2008; Motterlini and Otterbein, 2010). 
1.4.1 Pharmacodynamics of CO 
As a pharmacological agent, CO is unique in that it is highly diffusible and stable signalling 
molecule that is not readily metabolised by intracellular mechanisms (Knauert et al., 2013; 
Queiroga et al., 2012). There are two known mechanisms of CO action. The first being that CO 
specifically targets haem-based proteins like soluble guanylate cyclase (sGC) and neuronal 
nitric oxide synthase (nNOS) to recruit endogenous cellular signalling pathways to produce a 
response (Ma et al., 2007; Thom et al., 2004). Alternatively, CO binds to and inhibits 
mitochondrial complex IV (also a haem-based protein) to potentiate the basal ROS leak from 
respiratory complexes I and III which act to propagate the CO signal (Alonso et al., 2003). 
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1.4.2 CO as a Preconditioning Agent 
1.4.2.1 CO and Mitochondrial Membrane Permeability 
As previously established, formation of the mPTP promotes MMP loss and cell death through 
several mechanisms. One mechanism of protection offered by CO is that it increases the MMP 
and therefore, the mitochondrial capacity to take up Ca2+ to reduce Ca2+-induced MMP loss 
mediated cell death (Figure 2) (Oliveira et al., 2016). Alteration in mitochondrial Ca2+ capacity 
due to CO infusion was suggested from rodent isolated hepatic mitochondria which exhibited 
altered Ca2+ sensitivity following 50 p.p.m. CO exposure for seven days (Piantadosi et al., 
2006). The observed effect was hypothesised to be achieved via ROS generated as a result of 
CO inhibition of complex IV (Figure 2) (Alonso et al., 2003). To support this hypothesis, the 
preservation of the MMP was lost when hepatocytes were treated with CO (10 μM) in 
combination with the antioxidant, β-carotene (1 μM) (Queiroga et al., 2011). An increase in the 
MMP and Ca2+ uptake capacity due to CO treatment (10 μM CORM-3) has been confirmed in 
mitochondria isolated from cardiomyocytes originating in mice exhibiting metabolic syndrome 
(Lancel et al., 2012). Additionally, CO also prevents MMP mediated cell death by inhibiting 
mitochondrial translocation of proapoptotic Bax and Bid activation while promoting the anti-
apoptotic expression of Bcl-2 in models of lung and cerebral ischaemia (Panahian et al., 1999; 
Wang et al., 2007; Zhang et al., 2003). 
1.4.2.2 CO and Mitochondrial Uncoupling 
During ischaemia, succinate acts as an electron store in the absence of O2. Upon reperfusion, 
where the proton motive force is high due to the rapid presentation of H+, succinate readily 
presents electrons to drive reverse electron transport at mitochondrial complex I (Chouchani et 
al., 2014). This results in the incomplete reduction of O2 to form O2
•– (Murphy, 2009). 
Uncoupling of mitochondrial respiration from ATP synthesis results in the leakage and 
dissipation of the proton motive force to prevent the synthesis of ROS (as well as ATP) (Gnaiger 
et al., 1998; Massari et al., 1996). CO acts as a protective conditioning agent by mildly 
uncoupling mitochondrial respiration to limit oxidative stress upon reperfusion. This 
mechanism of action is based on several findings by Iacono et al. (2011) in isolated cardiac 
mitochondria. CO released by the CO-releasing molecule (CORM), CORM-3 (20 μM), 
increased O2 consumption in the absence of exogenous adenosine diphosphate (ADP), 
indicating an uncoupling effect between O2 reduction and ATP synthesis. CO also upregulated 
reverse electron transport from complex II to complex I when respiration was initiated at 
complex II by succinate. Lastly, CO induced decrease in MMP was found to be reversed in the 
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presence of uncoupling protein/adenine nucleotide translocase inhibitors, suggesting that it 
modulates these proteins to enhance the uncoupling effect (Lo Iacono et al., 2011). A more 
recent study found CO directly targets the phosphate carrier to increase proton and phosphate 
transport into the mitochondria to produce an uncoupling effect (Long et al., 2014). 
1.4.2.3 CO and Mitochondrial Energetics 
Inhibition of complex II and complex IV by CO consequently alters mitochondrial energetics 
(Lo Iacono et al., 2011; Queiroga et al., 2012). In fact, cells treated with CO react in a 
compensatory manner to increase ATP production. Almeida et al. (2012) found that astrocytes 
treated with exogenous CO (50 μM) exhibited a decreased ratio between lactate production and 
glucose consumption (indicative of favouring oxidative phosphorylation/aerobic respiration) 
(Almeida et al., 2012). This increase in ATP by CO has been confirmed in in vivo models to 
act as a protective mechanism to attenuate IR injury. Pigs exposed to gaseous CO (250 p.p.m. 
for two hours) subjected to CABG surgery with cardioplegic arrest not only exhibited an 
increase in the ATP to ADP ratio at the end of one-hour of reperfusion, but also an increase in 
phosphocreatinine which was correlated to reduced oedema and apoptosis (Lavitrano et al., 
2004). In fact, during the ischaemic period, pigs subjected to coronary artery occlusion also 
exhibited a decreased lactate production to glucose consumption ratio, indicating that CO alters 
mitochondrial metabolism during the ischaemic phase to preserve cardiac function (Lavitrano 
et al., 2004). 
1.4.2.4 CO and Protein Kinase C Epsilon Activation 
Protein kinase C epsilon (PKCε) is a Ca2+ independent, serine/threonine kinase that is linked to 
muscle contraction, mechanical force adaptation and cardioprotection (Ali and Sarna, 2002; Liu 
et al., 1999; Traub et al., 1997). Regarding PKCε activation during preconditioning, it is known 
to translocate to either the mitochondrial or sarcolemmal membrane (Fryer et al., 2001; Ping et 
al., 1997). Inside the mitochondria, PKCε binds to the anchoring protein receptors for activated 
C kinases (RACKs) which colocalises PKCε with specific proteins to produce a 
cardioprotective effect (Csukai et al., 1997; Mochly-Rosen, 1995). It is hypothesised that 
RACKs colocalise PKCε with K+ ATP (KATP) channels. Endogenously, the KATP channel is 
inhibited by high levels of ATP. When ATP levels fall, the KATP channel opens in an attempt 
to restore the MMP and therefore ATP synthesis through H+ efflux (Ashcroft and Ashcroft, 
1990). Preconditioning mediated KATP phosphorylation and hence opening by PKCε results in 
a reduced MMP to produce a mild amount of ROS that exposes the mitochondria to a bout of 
simulated IR injury (Liu et al., 1999). This bout braces cardiomyocytes for an ischaemic 
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episode (Kornfeld et al., 2015). Additionally, during ischaemia, preconditioned KATP opening 
stabilises the MMP, reduces the mitochondrial Ca2+ overload and decreases ROS formation 
while PKCε may also phosphorylate mPTP to preserve mitochondrial function (Tinker et al., 
2014). Upon reperfusion, PKCε also activates aldehyde dehydrogenase 2 to reduce internal 
mitochondrial ROS (Figure 2) (Kornfeld et al., 2015). 
CO induced mitochondrial ROS generation activates PKCε translocation from the cytosol into 
the particulate (membrane bound) fraction (Inagaki et al., 2006; Kornfeld et al., 2015; 
Piantadosi, 2008). This translocation has been implicated as a critical mediator for CO’s 
observed preconditioning effect (Figure 2) and has been confirmed in cultured neonatal rat 
cardiomyocytes, isolated rat hearts and rabbit myocardium subjected to CO preconditioning 
prior to IR injury (Adams et al., 2017; Gray et al., 1997; Mitchell et al., 1995; Ping et al., 1997). 
1.4.2.5 CO and Ca2+ Channel Inhibition 
As a preconditioning agent, CO also modulates Ca2+ signalling. CO inhibits the L-type Ca2+ 
channel (LTCC) (Figure 2) in a mitochondrial ROS-dependent manner in human embryonic 
kidney (HEK) cells stably expressing the human cardiac Cav1.2 subunit (Scragg et al., 2008). 
In normal cardiac contractions, extracellular Ca2+ influx through the LTCC is essential to trigger 
Ca2+ release from the SR via Ca2+ induced Ca2+ release (CICR) (Bers, 2002b). CO mediated 
inhibition of LTCC has been proposed to be cardioprotective upon reperfusion by preventing 
the high extracellular Ca2+ load from the blood inducing an excessive CICR response (Elies et 
al., 2014). This effect was reversed in the presence of the mitochondrial complex III inhibitor, 
antimycin A, or the mitochondrial targeted anti-oxidant, MitoQ, by preventing the ROS 
generated from CO mediated electron transport chain inhibition reaching the LTCC. Three 
cysteine residues within the LTCC were found to be essential for CO mediated LTCC inhibition 




Figure 2. CO as a pharmacological preconditioning agent. Preconditioning by CO is 
achieved by inhibition of the L-type Ca2+ channel (LTCC) and complex IV of the mitochondrial 
respiratory chain, the latter of which generates reactive oxygen species (ROS). This ROS has 
been linked to preventing mitochondrial membrane potential (MMP) loss and the translocation 
of protein kinase C epsilon (PKCε) into the mitochondria. PKCε may go on to activate aldehyde 
dehydrogenase 2 (ALDH2) and mitochondrial KATP channels or inhibit the formation of 
mitochondrial permeability transition pore (mPTP) which have all been linked to 
cardioprotection. Additionally, CO mildly uncouples mitochondria to prevent the formation of 
a large burst of ROS upon reperfusion while also preserving mitochondrial energetics (adapted 
from Kornfeld et al. 2015). 
1.5 CORMS 
1.5.1 Delivery of CO via CORMs 
It is evident that although CO exhibits relatively simple pharmacokinetics (due to its inability 
to be metabolised) and pharmacodynamics (as CO can only target haem-based proteins); 
inhalation delivery of CO faces many challenges due to the abundance of haem or haem-based 
proteins in the blood and cells (Bilban et al., 2008; Motterlini and Otterbein, 2010). One such 
challenge includes the lack of selectivity of exposure to gaseous CO to produce the intended 
response at the desired organ (e.g. to precondition the heart). To overcome this, recent efforts 
have focused on developing a clinically relevant CORM. CORMs allow for the controlled 
release of CO to the site of interest (Steiger et al., 2017). Most traditional CORMs were based 
on transition-metal carbonyl complexes usually consisting of Mn, Ru and Fe (Motterlini et al., 
2005). CORMs can be chemically manipulated to alter their pharmacokinetic and 
pharmacodynamic profile such as their rate of CO release. This therefore, allows the 
establishment of a therapeutically relevant free CO concentration while keeping 
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carboxyhaemogobin (COHb) concentration low (Steiger et al., 2017). Early CORMs (CORM-
2 - [Ru(CO)3Cl2]) suffered from low water solubility and high toxicity but newer generations 
of CORMs (e.g. CORM-3 – [Ru(CO)3Cl(glycinate)]), consisting of organic ligands which 
surround and form a co-ordination complex around the transition metal centre, increase the 
compounds water solubility (Foresti et al., 2004). 
1.5.2 Efficacy of CORMs as a Preconditioning Agent 
CORMs have contributed immensely to the understanding of the mechanism of action of CO 
and as such, have proven the efficacy of CO as a preconditioning agent ex vivo and in vivo. In 
isolated rat hearts subjected to IR injury, hearts pre-treated with CORM-2 exhibited 
significantly improved recovery of post-ischaemic haemodynamic parameters such as 
systolic/diastolic pressure, left ventricular developed pressure (LVDP), heart rate, coronary 
flow rate and reduced MI size. This improvement in cardiac function was correlated with a 
reduced level of myocardial injury biomarkers such as lactate dehydrogenase (LDH) and 
creatinine kinase in the coronary effluent (Soni et al., 2012). It is shown that CORM-2 induces 
preconditioning in isolated rat hearts via the activation of p38 mitogen activate protein kinase 
(MAPK), PKCε and KATP channels prior to ischaemia as well as phosphoinositide 3-kinase 
(PI3-K) pathway during reperfusion (Soni et al., 2012). CORM-3 has also been proven to be 
cardioprotective by improving haemodynamic parameters following coronary artery occlusion 
in isolated mouse hearts (Stein et al., 2005). 
In vivo, CORM-3 offers protection against IR injury. Following a coronary artery occlusion and 
reperfusion, pre-treatment with CORM-3 for 24-hours reduced infarct size 48-hours after IR 
injury. Stein et al. (2012) proposes that this effect was a result of the activation of transcription 
factors nuclear factor kappa B (NF-κB), signal transducers and activators of transcription 
(STAT) 1/3 and nuclear factor-erythroid-2-related factor 2 (Nrf2) resulting in the synthesis and 
activation of cardioprotective/anti-apoptotic factors leading to a significant reduction in 
biomarkers of cardiac damage (Stein et al., 2012). 
1.5.3 Toxicity of CORMs and Current Directions 
A fundamental flaw with CORMs are that they consist of a transition metal core that are 
inherently toxic. In HEK and Madin-Darby canine kidney cells, respectively, CORM-2 and the 
inactive form unable to release CO, iCORM-2, significantly reduced cell viability in a dose-
dependent manner (20-100 μM). This increase in cell death was attributed to an increase in the 
expression of apoptotic mediators caspase 3 and 7 (Winburn et al., 2012). As a result, focus has 
shifted to creating organic, water soluble, metal free CORMs which include boranocarbonates 
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and aldehydes such as CORM-A1 (Na2H3BCO2). CORM-A1 releases CO when in contact with 
water and at a very slow rate under physiological conditions (pH 7.4) (Motterlini et al., 2005). 
More recent and novel metal free approaches involve the generation of CO through the ‘click 
and release’ reaction, more formally known as the Diels Alder reaction which involves the 
interaction of two organic educts. These ‘click and release’ compounds have been modified 
with various lengths of alkynes attached to the diene CO component to release CO at various 
rates ranging from two-minutes to one-week (Ji et al., 2016). However, dimethyl sulfoxide 
(DMSO) is required to solubilise these agents (Kueh et al., 2017). Alternatively, bridged 
carbonyl compounds like norborn-2-en-7-ones undergo cheletropic loss to release CO. A major 
advantage of using these compounds is that they are triggered in a pH-dependent manner, 
produce a more predictable rate of CO release and form a benzene by-product which exhibits 
significantly less residual toxicity compared to metal-based CORMs. Furthermore, they are 
readily dissolvable in water to remove the need to use toxic organic solvents (Kueh et al., 2017). 
Our lab group is extensively working with these norbornenone/norbornadienone derivatives 
termed organic CO-releasing molecules (oCOms) as a preconditioning agent. 
1.6 Efficacy of oCOms 
Previous data from our lab group has shown that oCOms are an effective preconditioning agent. 
In isolated rat hearts, pre-treatment with the oCOm derivative, oCOm-21, for 10-minutes prior 
to a 30-minute global ischaemic episode (achieved via cessation of perfusion buffer) 
significantly preserved haemodynamic parameters, reduced cardiac cell death and decreased 
cytosolic damage measured via lactate dehydrogenase (LDH) leakage into the coronary effluent 
post-ischaemia. Furthermore, treatment with the selective PKCε inhibitor chelerythrine in 
combination with oCOm-21 reversed any observed preservation of post-ischaemia 
haemodynamic parameters, implicating that the mechanism of oCOm-21 aligns with the 
literature where CO acts as a cardioprotective agent through PKCε activation (Adams et al., 
2017). We have confirmed the efficacy of oCOm-21 as a preconditioning agent in both 
normotrophic and hypertrophic CYP1A1/Ren-2 rat hearts subsequent to hypertension (Chau et 
al., 2018). In CYP1A1/Ren-2 rats subjected to IR injury, pre-treatment with oCOm-21 
preserved haemodynamic parameters following a 30-minute ischaemic episode and reduced 
LDH leakage during reperfusion (Chau et al., 2018). 
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1.7 Cardiac Contraction and Inotropy – The Significance of Ca2+ 
1.7.1 Excitation-Contraction Coupling 
Ca2+ contributes to the generation of the cardiac action potential and the physical contraction 
of the heart, a process known as excitation-contraction coupling. Within the heart, the sinoatrial 
node spontaneously depolarises to generate an action potential which propagates throughout 
the heart. This propagation initially occurs between atrial cells through gap junctions followed 
by conduction fibres which include the bundle of His and Purkinje fibres and thus, eventually 
leads to the activation of ventricular cardiomyocytes (Fearnley et al., 2011). At ventricular 
cardiomyocytes, an action potential causes sarcolemmal membrane depolarisation which 
activates Ca2+ influx through the voltage-gated LTCC. Inward Ca2+ influx triggers the opening 
of RyR2 and therefore, the release of SR Ca2+ via CICR (Figure 3). Raising intracellular [Ca2+] 
([Ca2+]i) allows Ca
2+ to freely diffuse into adjacent cardiomyocytes and bind to proteins 
resulting in their activation (Fearnley et al., 2011; Kuo and Ehrlich, 2015). 
 
Figure 3. Excitation-contraction coupling. Depolarisation of the sarcolemma allows opening 
of the L-type Ca2+ channel (LTCC) and Ca2+ induced Ca2+ release (CICR) resulting in Ca2+ 
release from the sarcoplasmic (SR) via the ryanodine 2 receptor (RyR2). Ca2+ binding to 
myofilament proteins produces a cardiac contraction. Upon completion of a contraction, Ca2+ 
is stored in the SR by the sarcoplasmic endoreticulum Ca2+ ATPase (SERCA), a Ca2+ reuptake 
channel, or the mitochondria by the mitochondrial uniporter. Alternatively, Ca2+ is expelled via 




1.7.2 Cross-bridge Cycling 
A primary protein that Ca2+ binds to with regards to a cardiac contraction following CICR is 
troponin C (cTnC). Ca2+ binding to cTnC induces conformational changes to the tropomyosin 
band to expose the myosin binding site on the actin filament. At rest, the myosin head is pre-
energised as it partially hydrolyses the ATP bound to it (Figure 4). Upon exposure of the myosin 
binding site, the myosin head binds to the actin filament and performs a ‘power stroke,’ leading 
to the actin filament being pulled towards the centre of the sarcomere which shortens muscle 
length and results as a cardiac contraction (Figure 4). The performance of a ‘power stroke’ by 
the myosin head consumes ATP, forming ADP and inorganic phosphate as by-products which 
are released by the myosin head. Rebinding of ATP to the myosin head dissociates it from the 
actin filament which is then partially hydrolysed to prime the myosin head for the next 
contraction (Figure 4). This interaction between the myosin head and actin filament is known 
as cross-bridge cycling. As long as cytosolic [Ca2+] remains elevated to expose the myosin 
binding site on the actin filament, myosin will continuously be re-energised and perform a 
contraction until [Ca2+]i falls (Figure 4). Ca
2+ levels fall due the intrinsic activity of the SERCA, 
which sequesters Ca2+ to replenish the SR Ca2+ store. Additionally, raising [Ca2+]i also activates 
the NCX antiporter to promote membrane depolarisation and the Na+ electrochemical gradient 
is utilised to power Ca2+ efflux. These Ca2+ extrusion mechanisms result in cardiac muscle 
relaxation (Arner and Malmqvist, 1998; Geeves, 1991; Huxley, 1985). 
 
Figure 4. Myosin actin cross-bridge cycling. Primed myosin heads readily bind to the actin 
filament when Ca2+ binds to cardiac troponin C (cTnC) to expose the myosin binding site on 
the actin filament, forming a cross-bridge (1 and 2). A power stroke is performed and the cross-
bridge is disassembled (3 and 4). The process repeats until ATP and Ca2+ levels decrease 
(Tortora, 2006).  
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1.7.3 Store Overload Induced Ca2+ Release 
In the absence of membrane depolarisation and CICR, spontaneous Ca2+ release may occur 
when SR content reaches a determined threshold resulting in Ca2+ sparks, waves and 
oscillations. This un-stimulated release of Ca2+ is termed store overload induced Ca2+ release 
(SOICR) (Jones et al., 2008). The initiation of the release of Ca2+ in this manner is dependent 
on the internal SR [Ca2+] which is primarily driven by SERCA activity and the gating properties 
of RyR2. When SR [Ca2+] accumulates and reaches the “release threshold,” RyR2 will open 
and continue to release SR Ca2+ until it decreases to the “termination threshold” (Jiang et al., 
2004b; Jones et al., 2008; MacLennan and Chen, 2009). 
With particular disease states (such as catecholaminergic polymorphic ventricular tachycardia 
(CPVT)), stressors (IR injury) or pharmacological agents (digitalis toxicity and caffeine), 
SOICR release threshold and termination can be altered (Figure 5) (Lakatta, 1992; Tong et al., 
1999). The release threshold is often pre-determined by RyR2 open probability. CPVT 
mutations in RyR2 have been linked to a reduced release threshold, an enhanced propensity for 
SOICR and hence susceptibility to arrhythmia in these patients (Jiang et al., 2005; Jiang et al., 
2004b; Liu et al., 2009). Modification of SERCA activity and its regulatory protein 
phospholamban may work synergistically with or separately from RyR2 alterations to increase 
the incidence of SOICR (Figure 5) (MacLennan and Chen, 2009). The probability of SOICR 
may also be increased through modifications of calsequestrin 2 (CASQ2), an internal SR 
luminal protein that binds to Ca2+ with a low affinity but high capacity (Park et al., 2003; Royer 
and Rios, 2009). Recessive mutations in the CASQ2 gene lead to truncation and/or misfolding 
of the protein resulting in a reduced luminal SR Ca2+ buffering capacity and therefore, a CPVT 
phenotype (Knollmann, 2009; MacLennan and Chen, 2009). Alternatively, termination 
threshold may be reduced and although this does not change the rate of SOICR, the amount of 
Ca2+ released from the SR by RyR2 is. Decreasing both the release and termination threshold 
increases the occurrence of SOICR which manifests into cardiac arrhythmias by changing the 
surface membrane potential and increasing the cytosolic [Ca2+] during diastole to produce 
delayed after depolarisations (Figure 5) (Bers, 2002a). 
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Figure 5. The changing states of SOICR. In the absence of sarcolemmal membrane 
depolarisation, [Ca2+] in the sarcoplasmic reticulum (SR) (blue) increases due to sarcoplasmic 
endoreticulum Ca2+ ATPase (SERCA) activity and is released by the ryanodine 2 receptor 
(RyR2) when the release threshold is reached. A) Indicates a non-altered phenotype of SOICR; 
B) the release threshold is reduced resulting in a mild amount of Ca2+ release at a lower luminal 
SR [Ca2+]; C) termination threshold is reduced indicating that RyR2 remains open for longer to 
release more SR Ca2+ and D) both the release and termination threshold is reduced resulting in 
a higher incidence of SOICR and arrhythmia. Adapted from Jiang et al. (2004) and MacLennan 
and Chen, (2009). 
1.8 S-nitrosylation 
Nitric oxide (NO) plays an important role in the regulation of cardiac function (Sun et al., 
2006b). NO is formed through NO synthases (NOS). NOS catalyses the conversion of L-
arginine and O2 to L-citrulline and NO in the presence of reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) and BH4. Within cardiomyocytes, both the endothelial and 
neuronal isoforms of NOS (eNOS and nNOS, respectively), are constitutively active to produce 
NO but are localised within different domains of the cell (Barouch et al., 2002; Feron et al., 
1998). eNOS is situated within the folds of the sarcolemma known as caveolae while nNOS is 
primarily located at the SR membrane (Barouch et al., 2002). The third and final isoform, 
inducible NOS (iNOS) is only upregulated in the presence of inflammatory mediators (Bolli, 
2001). Consequently, the cellular localisation of each NOS isoform results in the activation (or 
inactivation) of unique cellular signalling cascades. One such mechanism with which this can 
be achieved is through NO interacting with protein cysteine residues to form a S-nitrosothiol 
(SNO) post-translational modification (a process known as S-nitrosylation) (Hess et al., 2005). 
17 
S-nitrosylation of proteins results in changes in protein conformation and has been linked to 
cardioprotection such as improved recovery of haemodynamic parameters following cardiac 
ischaemic insult (Kohr et al., 2011). 
The formation of S-nitrosylation is dependent on the microenvironment surrounding the 
cysteine residue. NO can only directly interact with cysteine residues in the presence of an 
electron acceptor (Sun et al., 2006b). Other means of SNO formation include NO complexed 
to transition metals which can interact with cysteine residues or through transnitrosylation (the 
transfer of the NO motif from one protein to another) supplied through the presentation of S-
nitrosoglutathione (GSNO) or S-nitrosocysteine (CysNO) (Hogg, 2002; Muller et al., 2002). 
The extent of SNO formation and therefore, the effectiveness of NO as a signalling molecule is 
also influenced by the immediate redox state of the cell. The presence of other ROS such as O2, 
O2
•– and antioxidants can greatly determine what products are (or are not) made. In the presence 
of O2, NO can directly and readily form N2O3 via autoxidation which exhibits the potential to 
S-nitrosylate proteins (Sun et al., 2006b). Alternatively, NO can react with O2
•– to form 
peroxynitrite (ONOO–), a powerful oxidant which can damage cardiomyocytes through free 
thiol oxidation, nitration of tyrosine residues and lipid peroxidation (Hare and Stamler, 2005). 
ONOO– is predominantly associated with negative cardiac outcomes via the irreversible 
nitration of proteins (Ronson et al., 1999). In the presence of an antioxidant the signalling 
potential of NO is negated (Sun et al., 2006b). 
Features surrounding a specified cysteine residue can greatly influence the likelihood and 
success of S-nitrosylation formation. Adjacent amino acid residues can hinder the accessibility 
of ROS to the cysteine residue and/or make the pH surrounding the cysteine thiol more acidic 
or basic and thus, control the local thiol pKa and nucleophilicity (Hess et al., 2005). Under 
physiological conditions, cysteine thiol residues are protonated due to their high pKa (greater 
than 8.5). However, surrounding amino acids can manipulate the microenvironment 
surrounding the cysteine thiol residue to be more hydrophobic and therefore, decrease the pKa 
to 7.5. Lowering the pKa of specific cysteine thiols makes them more likely to be present in 
their deprotonated, “hyper-reactive” state (Cys-S–). In the absence of electron acceptors, NO 
lacks the intrinsic ability to directly modify cysteine thiol residues (Donoso et al., 2011; Liu et 
al., 1998; Nedospasov et al., 2000). Hyper-reactive cysteines, however, are readily targeted by 
NO and more susceptible to reversible modifications like S-nitrosylation. This is because ROS 
act as an oxidising agent to prime the cysteine residues for NO interaction and therefore, the 
formation of S-nitrosylation (Donoso et al., 2011). 
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1.8.1 Preconditioning and S-nitrosylation 
Cardioprotective effects of preconditioning (either surgical or pharmacological) have been 
attributed to the upregulation of S-nitrosylation of several proteins and several NO-donors 
induce S-nitrosylation to mimic a cardioprotective, preconditioning-like effect (Sun et al., 
2007). S-nitrosylation of cysteine residues prior to IR injury may attenuate ROS/reactive 
nitrogen species (RNS) induced damage by: 1) acting as a protective molecular shield to prevent 
the irreversible oxidation of cysteine thiols; 2) modulate Ca2+ handling proteins such as 
inhibiting the LTCC to decrease the Ca2+ influx or activating SERCA to reduce the cytosolic 
Ca2+ overload during IR injury and 3) preserving mitochondrial energetics and preventing the 
loss of the MMP through F1F0 ATPase inhibition, preventing mitochondrial Ca2+ uptake and 
hence mPTP mediated cardiomyocyte death (Becker, 2004; Eu et al., 2000; Martinez-Ruiz and 
Lamas, 2007; Sun and Murphy, 2010; Sun et al., 2006a; Sun et al., 2006b; Waring, 2005). 
1.8.2 S-nitrosylation of RyR2 as a Mechanism of Inotropy and Protection 
RyR2 is a homotetrameric channel responsible for Ca2+ release from the SR upon CICR 
(Fabiato, 1983; Fill and Copello, 2002). Initial studies that examined S-nitrosylation of RyR2 
purified from canine cardiac SR determined that of a possible 364 cysteine residues, 84 were 
susceptible to S-nitrosylation and at endogenous levels, approximately only one cysteine 
residue in every six complete RyR2 channels exhibited S-nitrosylation. Application of 
additional NO through GSNO raised the amount of S-nitrosylation to 11 modified cysteines per 
tetramer and this was correlated to a three-fold increase in the open probability of RyR2 (Xu et 
al., 1998). Increased open probability of RyR2 has also been associated with the NO-donor, 
SNAP, but in a biphasic manner. Low dose SNAP (0.1-10 μM) produced an inotropic response 
correlated with increased S-nitrosylation that eventually decreased with higher doses (100 μM). 
The negative inotropic effect of SNAP (100 μM) found by Gonzalez et al. (2008) was attributed 
to an increase in cyclic guanosine monophosphate (cGMP), a by-product of sGC (Gonzalez et 
al., 2008). Additional studies confirmed that high doses of NO correlated to excessive S-
nitrosylation of RyR2 linked to irreversible channel activation (Gonzalez et al., 2007; Xu et al., 
1998). 
1.9 oCOm-21 as a S-nitrosylating Agent of RyR2 
CO exhibits the natural, intrinsic ability to target nNOS and subsequently, the potential to 
modulate S-nitrosylation of RyR2 (Sato et al., 1998; Tetreau et al., 1999). As a signalling 
molecule, CO released by oCOm-21 provides many advantages over NO-donors. Firstly, 
unpublished data by our lab group has shown that oCOm-21 is readily taken up by cells and 
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only release CO once inside the cytosol at physiological pH. Secondly, as CO is a stable 
signalling molecule, a more persistent response is achieved while avoiding nitrosative stress via 
NO-donors (Andreadou et al., 2015; Farrugia and Szurszewski, 2014; Motterlini and Foresti, 
2017). Lastly, as CO exhibits an extremely high specificity for haem, non-specific and off-
target effects by NO-donors are mitigated (Miller and Megson, 2007; Steiger et al., 2017). This 
may explain why NO-donors as a preconditioning agent have failed clinical trials and 
consequently suggest that alternative conditioning agents need to be examined (Spath et al., 
2016). NO as a conditioning molecule might not be inherently flawed although how it is 
delivered might. Literature acknowledges that there is co-dependence between the haem/CO 
and NOS/NO signalling pathways but the potential significance of this in myocardium is to be 
determined (Motterlini and Otterbein, 2010). 
Studies have confirmed that CO upregulates NO through the binding of nNOS. In HEK293 
cells transfected with nNOS and the recombinant human NaV1.5 channel, CORM-2 (2 μM) was 
required to activate nNOS to S-nitrosylate and hence, inhibit the NaV1.5 channel (Elies et al., 
2014). However, such a model may lack alternative CO-binding sites that may predominate in 
a cardiomyocyte like myoglobin and alternative studies focus on clinically toxic doses of CO 
that activate nNOS. Prior work performed by Dallas et al. (2012) confirmed that 30 μM CORM-
3 activates nNOS in isolated rat cardiomyocytes from the right ventricle resulting in an 
arrhythmic phenotype and that in vivo, inhalation of 500 ppm of CO in rats was proarrhythmic 
(Dallas et al., 2012). Furthermore, it is known that nNOS co-immunoprecipitates with RyR2 
suggesting an endogenous mechanism of S-nitrosylation (Lim et al., 2008). In both rat and 
human myocardium, a protein-protein link exists between nNOS and RyR2 to form an 
interactive complex (Bendall et al., 2004; Damy et al., 2004; Lim et al., 2008). Knowing that 
NO is labile with a short diffusion distance, such co-localization would indicate a highly 
specific interaction between the two complexes (Pacher et al., 2007; Sun and Murphy, 2010). 
CO would only make S-nitrosylation of RyR2 through nNOS more probable by supplying a 
source of O2
•– (through ATP synthase inhibition) to prime the cysteine thiol residues for S-
nitrosylation (Donoso et al., 2011; Piantadosi, 2008). S-nitrosylation of RyR2 by CO would be 
further facilitated by the fact that the mitochondrial outer membrane is attached to the SR to 
decrease the diffusion distance of O2
•– (Boncompagni et al., 2009; Hayashi et al., 2009). 
Recently, Kaczara et al. (2018) determined an association between CO mediated nNOS 




In both preliminary studies by this lab group involving normal and hypertensive rat hearts, 
respectively, the 10-minute pre-treatment period with oCOm-21 significantly increased the 
systolic pressure and subsequently, the LVDP (Adams et al., 2017; Chau et al., 2018). This 
suggests that oCOm-21 is an active inotropic agent. Although CO is known to induce 
vasodilation to increase coronary flow rate (of which was also confirmed in these studies) to 
increase the developed force (known as the Gregg’s phenomenon); the modulation and 
preservation of the coronary vasculature cannot solely explain the observed improvement of 
haemodynamic parameters compared to the untreated control group post-ischaemia in these 
studies, if at a fundamental level, the primary unit of contraction (the myofilament) is damaged 
due to e.g. ROS (Salavastru and Carmaciu, 1998). Furthermore, oCOm-21 treated hearts 
maintained an equivalent coronary flow rate compared to the untreated control group during 
reperfusion, negating the potential link between coronary flow rate increasing the force of 
contraction post-ischaemia. The current literature examining CO lacks investigation of the 
possible modulation of the contractile apparatuses of the heart to increase the force of 
contraction and in particular, any association of CO with RyR2 activity in cardiomyocytes. As 
a preconditioning agent, studies with CO fail to acknowledge that IR injury causes non-specific 
ROS damage throughout the cell and whether CO can protect intracellular proteins from this 
damage through a mechanism like S-nitrosylation. This study therefore attempts to find a 
mechanism of inotropy as a potential rationale which could be causally linked to the observed 
recovery of haemodynamics post-ischaemia by protecting against this non-specific ROS 
damage during IR injury. 
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2 Aims and Hypothesis 
The hypothesis of this study was that oCOm-21 exhibits an inotropic effect through S-
nitrosylation of RyR2. 
This study aimed to investigate whether oCOm-21 was an inotropic agent and whether it could 
S-nitrosylate proteins, in particular RyR2, to produce an inotropic effect. Confirmation was sort 
by addressing the following aims: 
1) To confirm that oCOm-21 was inotropic in isolated rat hearts 
2) That oCOm-21 mediated inotropy was through the modulation of intracellular Ca2+  
3) Determine whether oCOm-21 increased H2O2 and NO 
4) That oCOm-21 S-nitrosylates RyR2 through western blotting 




3.1 Materials and Reagents 
All materials and reagents were purchased from BDH Laboratory Supplies (Palmerston North, 
New Zealand) and Sigma Aldrich (Auckland, New Zealand) unless stated otherwise. 
3.2 Animals 
Male Sprague-Dawley rats (270-300g) were obtained from the University of Otago Animal 
Resource Unit (Dunedin, New Zealand). Animals were housed on a 12-hour light/dark cycle 
with access to standard rat chow and water ad libitum. Experiments were carried out with 
approval from the University of Otago Animal Ethics Committee (DET*20/16) and in 
accordance with the University of Otago Care and Use of Laboratory Animals guidelines. 
3.3 Langendorff Perfusion 
Isolated rat hearts were attached to the Langendorff rig and perfused retrogradely as previously 
described by Adlam et al. (2005). Briefly, animals were anaesthetized with halothane and 
monitored until stage III surgical anaesthesia was achieved (loss of pedal reflex and response 
to tail pinch). A laparotomy (surgical incision of the abdominal cavity) was then performed to 
allow for the administration of sodium heparin (100 IU) into the inferior vena cava. Hearts were 
quickly excised and placed in cold (4°C or 277 K) Krebs-Henseleit (KH) buffer (118 mM NaCl, 
4.7 mM KCl, 1.2 mM MgSO4, 1.23 mM KH2PO4, 24 mM NaHCO3, 1.2 mM CaCl2 and 11.1 
mM glucose (pH 7.4)) and was immediately cannulated via the aorta onto a retrograde 
Langendorff perfusion system. Hearts were perfused with oxygenated (95% O2/5% CO2), 37°C 
(310 K) KH buffer at a constant pressure (100 cm H2O). The pulmonary artery was cut to 
facilitate effluent drainage. The left atria was then removed to allow for insertion of an inflatable 
balloon (connected to a pressure transducer) into the left ventricle to measure left ventricular 
haemodynamic parameters using LabChart 8 Pro Software (ADInstruments, Castle Hill, 
Australia). Balloon inflation was performed until an end-diastolic pressure of 10 mmHg was 
achieved. The heart was then equilibrated for 20-minutes prior to any experimental 
manipulation. A left ventricular developed pressure (the difference between the systolic and 
diastolic pressure) of 90 mmHg was deemed the minimum requirement for the heart to be 
included in this study. 
  
23 
3.4 oCOm-21 and BP-21 Preparation 
Immediately before use, stock concentrations of oCOm-21 were made up in pH 6 H2O. The 
inactive by-product of oCOm-21 unable to release CO, BP-21, was dissolved in pH 8 H2O, 
sonicated three times and purged with gaseous N2 24 hours prior to experimentation. 
3.5 Langendorff Concentration-Response Experiments 
Hearts were allocated to only one of the following groups: oCOm-21 or BP-21. Administration 
of oCOm-21 and BP-21 was achieved via an infusion side port of the Langendorff apparatus 
using a Hamilton glass syringe (Hamilton, Reno, USA) mounted in a Bee Hive micro infusion 
pump (Bioanalytical Systems, West Lafayette, USA) as previously described by Vranyac-
Tramoundanas et al. (2011). Prepared stock concentrations of oCOm-21 and BP-21 (as 
previously described in section 3.4) were infused at a rate determined by the coronary flow rate 
of the heart, defined as the total coronary effluent over one minute. Rate of drug infusion was 
based on the metric of 0.5 µL of compound per 1 mL coronary flow rate. Hearts were exposed 
to successive 10-minute drug infusion (Figure 6A) to 10-minute drug free wash periods until a 
concentration-response curve was generated (1 – 10 µM). Change in haemodynamic parameters 
due to oCOm-21 or BP-21 infusion was expressed as a fold difference to the drug free wash 
period that preceded it. 
3.6 Langendorff Concentration-Response Experiments in the Presence of L-NAME 
Hearts under this combination drug infusion were exposed to 5-minutes of N(ω)-nitro-L-
arginine methyl ester (L-NAME, 4 µM) prior to co-infusion with the desired oCOm-21 
concentration for 10-minutes using the same Langendorff equipment and setup as previously 
described in section 3.3 and 3.5 (Figure 6B). Following this, a 10-minute washout was 
performed to remove any oCOm-21 and the aforementioned process was repeated until a 
concentration-response curve was generated with oCOm-21 (1 – 10 µM) (Figure 6B). 
The concentration of L-NAME (4 μM) was chosen for this study based on previous findings by 
Kobara et al. (2003) and preliminary experimental work (data not shown) where L-NAME did 
not alter coronary flow rate or haemodynamic parameters. 
The change in haemodynamic parameters due to oCOm-21 infusion was expressed as a fold 




Figure 6. A schematic of the Langendorff experimental protocols. A) Representation of the 
protocol used to administer oCOm-21 to achieve a concentration-response curve (repetition of 
a 10-minute infusion followed by a 10-minute drug free wash period). B) The experimental 
protocol where L-NAME was infused for 5-minutes prior to co-infusion with the desired 
oCOm-21 concentration followed by a 10-minute drug free wash period until a concentration-
response curve was generated. 
3.7 Generation of Tetracycline Inducible RyR2/HEK293 Cells 
Stable inducible HEK293 cells expressing RyR2 were generated as previously described by 
Jiang et al. (2004a). 
3.8 Imaging RyR2/HEK293 Cells Loaded with Fluo-4 
Loading and subsequent imaging of RyR2/HEK293 cells containing Fluo-4 was performed as 
described by Zhang et al. (2014). Briefly, RyR2 expression in the stably transfected HEK293 
cells was induced by the addition tetracycline (0.1 μg/mL) 16-18-hours prior to 
experimentation. Cells were bathed in 0 mM Ca2+ Krebs-Ringer HEPES (KRH) buffer (125 
mM NaCl, 5 mM KCl, 25 mM HEPES, 1.2 mM MgCl2 and 6 mM glucose adjusted to pH 7.4 
with NaOH containing BSA (1 mg/ml)) and loaded with the acetoxymethyl ester (AM) form of 
the Ca2+ fluorescent indicator, Fluo-4-AM (Life Technologies). Fluo-4-AM was initially 
dissolved in DMSO and 12% (w/vol) Pluronic F127 (Life Technologies) prior to its addition in 
the Ca2+ free KRH buffer. Cells were mounted on an epi-fluorescence microscope (Nikon 
Eclipse Ti, 20 x plan-fluor objective) to monitor intracellular Ca2+ transients and while being 
continuously superfused with KRH buffer containing a range of CaCl2 concentrations (0.1 -  
1 mM). 
3.9 RyR2/HEK293 Ca2+ Imaging in the Presence of oCOm-21 
Each concentration of Ca2+ (0.1 – 1 mM) was applied for 4-minutes with or without oCOm-21 
(1 μM) at room temperature (21 ± 2°C or 294 ± 2° K). At the end of oCOm-21 dosing, 20 mM 
caffeine was applied for 2-minutes to deplete intracellular Ca2+ stores (Jiang et al., 2004a). 
Fluo-4 AM dye was excited at 470 nm (40 nm bandwidth) every 2 s with an exposure time of 
100 ms using a CoolLED system (Coherent Scientific Pty. Ltd, Australia). Fluorescence of 
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Fluo-4 was detected through a long pass dichroic mirror (495 nm) and a long pass emission 
filter (515 nm) by a CoolSNAP HQ2 CCD camera (Photometrics, AZ). Cytosolic Ca2+ 
fluorescence is expressed as F/F0, where F is fluorescence intensity at any time point while F0 
represents the average fluorescence intensity recorded with KRH solution containing 0 mM 
Ca2+. 
3.10 Rat Ventricular Cardiomyocyte Isolation 
Individual myocytes were isolated using a protocol as previously described by Zhou et al. 
(2011). Briefly, male Sprague Dawley rats as previously described in section 3.2 were subjected 
to an induction and maintenance isoflurane administration of 5 and 2 % isoflurane per 1 mL/min 
O2, respectively, until stage III surgical anaesthesia was achieved. A laparotomy was performed 
and the heart was quickly excised. Hearts were immediately cannulated through the aorta and 
perfused in a retrograde Langendorff manner with Ca2+-free KRH buffer (125 mM NaCl, 5 mM 
KCl, 25 mM HEPES, 6 mM glucose and 1.2 mM MgCl2 adjusted to pH 7.4). A peristaltic pump 
was used to maintain Ca2+-free KRH perfusion at a constant flow rate. Hearts were rinsed with 
Ca2+-free KRH for 5-minutes to remove any remaining blood prior to 10-minutes of oxygenated  
Ca2+-free KRH containing 0.2 mM CaCl2, 1 mg/mL Type 2 collagenase (Worthington 
Biochemicals, NJ, USA) and 40 µg/mL Type XIV Protease. The ventricles were removed, 
placed into 0.15 mM CaCl2 KRH and quickly minced to ~ 1 mm
3 blocks. The sample was then 
resuspended repeatedly with a wide-bore Pasteur pipette to produce a supernatant containing 
single cardiomyocytes. This supernatant was decanted and subjected to KRH buffer with 
progressively increasing [Ca2+] (0.2 -1 mM). Suspensions of isolated cardiomyocytes were 
loaded and washed in the presence or absence of Fluo-4-AM in 1 mM Ca2+-KRH for  
10-minutes, respectively. Incubation of cells in the absence of Fluo-4 allows for complete 
hydrolysis of the dye. 
3.11 Isolated Cardiomyocyte Imaging and oCOm-21 Infusion 
Following Fluo-4-AM loading, isolated cardiomyocytes were mounted on to coverslips placed 
on an epi-fluorescent microscope (Nikon Eclipse Ti, 20 x fluor objective, Coherent Scientific 
Pty. Ltd) which were constantly superfused with KRH. Individual coverslips were paced at  
1 Hz. Cardiomyocytes were exposed to a single fixed Ca2+ concentration (1 – 4 mM) during 
infusion of sequentially increasing oCOm-21 concentrations (1 - 10 µM). The untreated control 
period lasted 2-minutes and infusion of each oCOm-21 concentration occurred for 10-minutes. 
Following each concentration of oCOm-21, cells experienced 2-minutes no stimulation and the 
number of spontaneous contractions was recorded. Following the last concentration of oCOm-
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21, cells were infused with the RyR2 agonist caffeine (20 mM) to deplete intracellular SR Ca2+ 
stores and confirm cell viability (Jiang et al., 2004a). Experiments took place at room 
temperature (21 ± 2°C or 294 ± 2 K). Fluo-4 AM was excited at 470 nm (40 nm bandwidth) 
every 100 ms with an exposure time of 50 ms using a CoolLED system (Coherent Scientific 
Pty. Ltd). An Andor Zyla 4.2 Plus sCMOS camera (Coherent Scientific Pty. Ltd) recorded 
fluorescence of Fluo-4 though a long pass dichroic mirror (495 nm) and a long-pass emission 
filter (515 nm). Ca2+ fluorescence is expressed as F/F0, where F and F0 is the average peak 
fluorescence intensity of the last 30 seconds of an oCOm-21 concentration and the first 30 
seconds during the no stimulation period following 0 µM oCOm-21, respectively. 
3.12 Cell Culture 
AC16 human cardiomyocytes were cultured in T75 flasks containing growth medium 
consisting of Dulbecco’s Modified Eagle Media (DMEM) supplemented with 12.5% foetal 
bovine serum (FBS) and 1% penicillin/streptomycin (penstrep). Cells were grown to 80% 
confluency prior to experimental manipulation. 
3.13 ROS Determination 
Quantification of oxidative stress was achieved using the fluorescent probe 2',7'-
dichlorodihydrofluorescein diacetate (H2DCF-DA) (Bass et al., 1983). The diacetate, DA, motif 
allows the probe to readily pass through plasma membranes and it is only when the DA group 
is cleaved off by intracellular esterases that the oxidant sensitive H2DCF compound is produced. 
In the presence of oxidising species, H2DCF converts to DCF which can be quantified through 
fluorescence (LeBel et al., 1992). 
Upon achievement of sufficient confluency, AC16 cells were plated in Costar 96 well black 
plates at a density of 10,000 cells/well. Following a 24-hour incubation, cells were washed with 
phosphate buffered saline (PBS) and incubated in supplemented DMEM as previously 
mentioned containing H2DCF-DA (100 μM) originally dissolved in anhydrous DMSO (1% v/v) 
for 30-minutes. H2DCF-DA was then removed and cells were washed three times with PBS 
(Wang and Joseph, 1999). Cells were treated with oCOm-21 or BP-21 (0.1 - 100 μM) or H2O2 
(1 - 100 μM) which served as a positive control. All drug treatments were performed in 
triplicate. ROS formation was measured at an excitation and emission wavelength of 495 and 
525 nm, respectively. 
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3.14 Detection of NO Using DAF-FM DA 
Intracellular NO was investigated using the NO fluorescent probe 4-Amino-5-methylamino-
2',7'-difluorofluorescein diacetate (H2DAF-FM DA) (Invitrogen, Auckland, New Zealand). 
H2DAF-FM DA is a cell permeable fluorophore that is only susceptible to nitrosation by 
reactive nitrogen species upon intracellular esterase deacetylation (Kojima et al., 1999). AC16 
cells were plated in Costar 96 well black plates at various densities (10,000 – 50,000 cells/well). 
Following a 24-hour incubation, cells were washed with PBS and loaded with 2 μM DAF-FM 
DA (0.4% v/v DSMO) for 60-minutes prepared in media without phenol red and FBS (as both 
agents interfere with the fluorescence of the probe) (Miles et al., 1995; Misko et al., 1993). 
Cells were then washed three times with PBS and incubated with fresh supplemented growth 
medium for an additional 30-minutes to allow for complete de-esterification. oCOm-21 (100 
μM) and sodium nitroprusside (SNP, 1-100 μM) which served as a positive control was then 
applied to cells. The amount of NO was quantified via fluorescence at an excitation and 
emission wavelength of 495 and 515 nm, respectively. 
3.15 Spin Trapping with CPTIO 
Preparation of 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (CPTIO, 
100 μM) was achieved using PBS and then mixed with the spontaneous NO releasing agent, 
(Z)-1-[N-(3-aminopropyl)-N-(n-propyl)amino]diazen-1-ium-1,2-diolate (PAPA NONOate, 0.1 
100 μM) (Abcam, Cambridge, UK). CPTIO-PAPA NONOate mixtures were then incubated at 
310 K (37 °C) for 15-minutes (the approximate t½ of PAPA NONOate) before being loaded in 
a 50 µL glass capillary tubes (Hirschmann, 9600150). A Miniscope MS-5000 (Magnettech, 
Freiberg Instruments, Berlin, Germany) was then used for the detection and subsequent 
optimisation of the electron paramagnetic resonance (EPR) spectrum under the following range 
of conditions: X-band; magnetic field strength 335-340 mT, sweep time, 150 - 300 s; 
modulation 0.8 mT; accumulations, 1; microwave power, 1 and temperature, 293 – 296K (20 – 
23 °C). The specific parameters used for a given EPR spectrum are stated in the accompanying 
figure legend. 
3.16 Spin Trapping with Fe(DETC)2 
Stock concentrations of sodium diethyldithiocarbamate (DETC, 5 mM) and FeSO4.7H2O  
(1 mM) were separately dissolved in Ar degassed PBS. DETC and FeSO4 were then mixed in 
a 1:1 ratio prior to the addition of PAPA NONOate to the final concentration (1 nM – 100 μM). 
The solution was then incubated at 310 K (37 °C) for 15-minutes, loaded into 50 µL glass 
capillary tubes (Hirschmann, 9600150) and the formed Fe(DETC)2-NO EPR spectrum was 
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measured using a Miniscope MS-5000 (Magnettech, Freiberg Instruments, Berlin, Germany). 
EPR spectrum measurement and subsequent optimisation was performed under the following 
range of conditions: X band; magnetic field strength, 326 – 338 mT; sweep time, 60 s; 
modulation, 0.2 mT; accumulations, 5; microwave power, 50 and temperature 173 K (-100 °C) 
or 293 – 296 K (20 – 23 °C). Optimising the preparation of Fe(DETC)2 involved the addition 
of bovine serum albumin (BSA, 10 mg/mL) to the DETC stock solution to prevent any 
precipitation of the Fe(DETC)2 complex upon FeSO4.7H2O addition. An organic solvent 
extraction was also performed concentrate the Fe(DETC)2-NO produced to provide a stronger 
EPR spectrum. This was achieved using ethyl acetate in a 1:5 volume ratio to the Fe(DETC)2-
PAPA NONOate mixture. The formed solution was shaken for 3-minutes, centrifuged at 6000 
g for 6-minutes and the organic solvent layer was separated and kept in the dark at 4 °C (277 
K) until ready for EPR spectrum determination. This organic solvent layer was loaded into 50 
µL glass capillary tubes and measured with a Miniscope MS-5000 under the conditions as 
mentioned previously. The specific parameters used for a given EPR spectrum are stated in the 
accompanying figure legend. 
3.17 Force Measurement of Isolated Trabeculae 
Human right atrial appendage tissue was collected from patients undergoing cardiac surgery 
(coronary artery bypass graft surgery, atrial valve replacement or both) following written 
consent and approval by the Human and Disability Ethics Committee of New Zealand 
(LRS/12/01/001/AM13). Trabecula were isolated from the myocardial sample, placed into an 
experimental bath and attached between a micromanipulator and a force transducer. Force 
development were measured in isolated trabeculae as previously described by Lamberts et al. 
(2002). Trabecula were perfused with oxygenated (95% O2, 5% CO2) KH buffer (1.5 mM 
CaCl2, 18.5 mM NaCl, 4.5 mM KCl, 0.3 mM NaH2PO4, 1.0 mM MgCl2.6H2O, 25 mM NaHCO3 
and 11 mM glucose) at 36°C (309 K) while being continuous stimulated at 1 Hz (equivalent to 
60 beats per minute). Trabecula were stretched to the length at which the maximal isometric 
developed force was achieved (Lmax). The developed force was adjusted to the cross-sectional 
area (CSA) of the trabecula, which was assumed to be elliptical in nature, and was derived from 
the width of the trabecula where: CSA = ½ width x ¼ width x π. 
3.18 Infusion of oCOm-21 in Human Myocardial Samples 
Following establishment of a steady force of contraction, trabeculae were exposed to cycles of 
10-minute oCOm-21 (0.1-10 μM) infusion followed by a 10-minute wash period until a 
concentration-response curve was generated. Administration of oCOm-21 was achieved via an 
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infusion port using a Hamilton glass syringe (Hamilton, Reno, USA) mounted in a Bee Hive 
micro infusion pump (Bioanalytical Systems, West Lafayette, USA). The desired concentration 
of oCOm-21 (0.1 – 10 μM) was performed by adjusting the micro infusion pump so that the 
concentration coincided with the rate of infusion in μL/min (e.g. 0.1 μM administered at 0.1 
μL/min). Changes in cardiac parameters were measured with LabChart 8 Pro Software 
(ADInstruments, Castle Hill, Australia) and expressed as a fold difference to the drug free wash 
period immediately prior to the oCOm-21 concentration. 
3.19 Statistical Analysis 
All statistical data was analysed using GraphPad Prism 8 software (GraphPad Software Inc. 
San Diego, CA, USA). Langendorff, DCF-DA, DAF-FM, Ca2+ transient RyR2-HEK cell and 
human trabecula inotropy data were analysed using a two-way analysis of variance (ANOVA). 
Significant two-way ANOVA’s were coupled with a Bonferroni post hoc test to determine 
which comparison obtained a significant result. Isolated cardiomyocyte data was analysed using 
a one-way or two-way ANOVA coupled with a Dunnett’s post hoc test where appropriate. 
Regarding human inotropy data, corresponding patient information was analysed using a non-
parametric Mann-Whitney U test. All data are presented as mean ± the standard error of the 




4.1 Confirmation of oCOm-21 Derived CO Mediated Inotropy 
Isolated rat hearts were subjected to increasing individual concentrations of oCOm-21 (0.1 – 
10 μM) or BP-21 (0.1 – 10 μM) and to perfusion washes with the drug-free buffer (Figure 7 
and 8). Infusion of oCOm-21 (0.1 – 10 μM) increased developed pressure in a concentration-
dependent manner. This inotropic increase in developed pressure was reproducibly ablated 
during the subsequent 10-minute drug-free wash phase (Figure 7A) confirming that the oCOm-
21 effects were reversed by washing. Substitution of oCOm-21 with the depleted by-product 
BP-21 (0.1 – 10 μM), did not reproduce the inotropic effects seen with the active oCOm-21 
(Figure 7B). oCOm-21 (1 and 3 μM) significantly increased developed pressure (Figure 8) 
compared to 0.1 μM oCOm-21. Further increases of oCOm-21 concentration (10 μM) resulted 
in a decrease in the developed pressure, producing a biphasic concentration-response curve over 
this concentration range (0.1 – 10 μM). Overall oCOm-21 responses at 1 and 3 μM were 
significantly different to the responses elicited by BP-21 at equivalent concentrations  
(Figure 8). 
4.2 Inotropic Response to oCOm-21 in the Presence of L-NAME 
Infusion (5-minutes) of the NOS inhibitor L-NAME (4 μM) alone, did not significantly alter 
the baseline developed pressure measured during the preceding drug-free wash period (Figure 
7C). Addition of L-NAME (4 μM) blunted the oCOm-21-induced inotropic response seen 
earlier (Figure 7A). A rightward shifted, reduced maximal inotropic concentration-response 
curve was exhibited with the combination oCOm-21 + L-NAME (4 μM) infusion compared to 
oCOm-21 alone (Figure 8). In the presence of L-NAME (4 μM), a significant increase in 
developed pressure was only seen with 3 and 10 μM oCOm-21 compared to 0.1 μM oCOm-21 




Figure 7. Representative LV pressure recordings. A concentration-response was obtained in isolated rat hearts infused with: A) oCOm-21 (0.1 –  
10 μM); B) BP-21 (0.1 – 10 μM) and C) oCOm-21 (0.1 – 10 μM) in the presence of L-NAME. In A) and B) hearts were subjected to alternate 10-minute 
infusions with each individual concentration of oCOm-21 or BP-21 and washed for 10 minutes with drug-free buffer. In C) L-NAME was pre-infused 




































































Figure 8. Confirmation of oCOm-21 mediated inotropy in isolated Sprague-Dawley 
hearts. Hearts were infused in with oCOm-21 (●, 0.1 – 10 μM); BP-21 (■, 0.1 – 10 μM) or 
oCOm-21 (0.1 – 10 μM) + L-NAME (4 μM) (▲) (n = 5 for all groups). Data are represented 
as mean ± SEM and was analysed using a two-way repeated measures ANOVA with a 
Bonferroni post hoc test. *Significant oCOm-21 and BP-21 comparison at the same 
concentration, p ≤ 0.05. +Significant oCOm-21 and oCOm-21 + L-NAME (4 μM) comparison 
at the same concentration, p ≤ 0.05. ^Significant comparison between the indicated oCOm-21 
concentration and 0.1 μM oCOm-21, p < 0.05. ♦Significant comparison between the indicated 
oCOm-21 + L-NAME (4 μM) concentration and 0.1 μM oCOm-21 + L-NAME (4 μM),  
p ≤ 0.05. #Significant overall response comparison between oCOm-21 and BP-21, p ≤ 0.05. 
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4.3 oCOm-21 Effects on Isovolumetric Contraction and Relaxation Rate Parameters 
oCOm-21 infusion produced a similar biphasic concentration-response curve with regards to 
peak rate developed pressure to systole (dP/dTmax) and peak rate of pressure decline to diastole 
(dP/dTmin). A significant increase in dP/dTmax and dP/dTmin was obtained at 1 and 3 μM oCOm-
21 when both were compared against 0.1 μM oCOm-21 and to equivalent concentrations of 
BP-21 (1 and 3 μM, respectively) (Figure 9A and 9B). A difference in overall drug response 
was also seen when oCOm-21 was compared to BP-21 (Figure 9A and 9B). 
Furthermore, co-administration of oCOm-21 with L-NAME (4 μM) produced a significant 
blunting in dP/dTmax and dP/dTmin parameters (Figure 9A and 9B). L-NAME in the presence 
with oCOm-21 produced a rightward shift and reduction in maximal response to increasing 
oCOm-21 concentration (0.1 – 10 μM). Only 3 μM oCOm-21 + L-NAME (4 μM) produced a 
significant increase in dP/dTmax and dP/dTmin values compared to 0.1 μM oCOm-21 + L-NAME 
(4 μM) (Figure 9A and 9B). 
The LV relaxation time constant, tau represents the exponential decay of the ventricular 
pressure during isovolumetric relaxation (Thomas et al., 1992). oCOm-21 produced a steady, 
concentration-dependent increase in tau (Figure 9C), where responses to oCOm-21 were 
significantly different when compared to 0.1 μM oCOm-21. Co-administration of the NOS 
inhibitor, L-NAME (4 μM), with oCOm-21 obliterated this response while the inactive BP-21 
had no effect on tau (Figure 9C). 
Heart rate (Figure 9D) was not affected by either oCOm-21 (0.1 – 10 μM) or BP-21 (0.1 –  
10 μM) infusion. However, co-administration of L-NAME (4 μM) resulted in a significant 




Figure 9. Haemodynamic rate parameters following oCOm-21 administration. Hearts 
were infused in concentration-response manner with oCOm-21 (●, 0.1 – 10 μM), BP-21 (■, 0.1 
– 10 μM) or oCOm-21 (0.1 – 10 μM) + L-NAME (4 μM) (▲) (n = 5 for all treatment groups). 
Haemodynamic parameters: A) peak rate of pressure development to systole, dP/dTmax; B) peak 
rate of pressure decline to diastole, dP/dTmin; C) LV relaxation time constant tau and D) heart 
rate were monitored. Data are represented as mean ± SEM and was analysed using a two-way 
repeated measures ANOVA coupled with a Bonferroni post hoc test. *Significant oCOm-21 
and BP-21 at the same concentration, p ≤ 0.05. +Significant oCOm-21 and oCOm-21 +  
L-NAME (4 μM) comparison at the same concentration, p ≤ 0.05. ^Significant comparison 
between the indicated oCOm-21 concentration and 0.1 μM oCOm-21, p < 0.05. ♦Significant 
comparison between the indicated oCOm-21 + L-NAME (4 μM) concentration and 0.1 μM 
oCOm-21 + L-NAME (4 μM), p ≤ 0.05. XSignificant BP-21 and oCOm-21 + L-NAME (4 μM) 
comparison at the same concentration, p ≤ 0.05. #Significant overall response between  













































































































































4.4 SOICR from RyR2/HEK293 Cells Treated with oCOm-21 
Based on the previous results where a clear, positive inotropic response to oCOm-21 was 
obtained, the impact of oCOm-21 on the [Ca2+]i was investigated in HEK293 cells stably 
transfected with RyR2. Increasing the extracellular [Ca2+] produced a sigmoidal concentration-
response curve in the number of cells undergoing SOICR (Figure 10). Incubation of 
RyR2/HEK293 cells with an inotropic concentration of oCOm-21 (1 μM) however, failed to 
produce a significant effect on the number of cells undergoing SOICR when compared to 





































Figure 10. Percentage of cells experiencing SOICR in RyR2/HEK293 cells treated with 
oCOm-21. RyR2 stably transfected in HEK293 cells were either untreated controls (●) or cells 
treated with oCOm-21 (■, 1 μM) (n = 5 for both treatment groups). Data are represented as 
mean ± SEM and was analysed using a two-way repeated measures ANOVA with a Bonferroni 
post hoc test. *Significant difference in the number of cells undergoing SOICR at the indicated 
extracellular [Ca2+] and 0 mM extracellular [Ca2+] within the oCOm-21 (1 μM) infusion group, 
p ≤ 0.05. +Significant comparison between the indicated extracellular [Ca2+] and 0 mM 
extracellular [Ca2+] within the untreated control group, p ≤ 0.05. 
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4.5 Effect of oCOm-21 on [Ca2+]i in Isolated Rat Ventricular Cardiomyocytes 
Continued investigation of oCOm-21 mediated modulation of [Ca2+]i was performed in freshly 
prepared isolated rat cardiomyocytes. At the fixed extracellular [Ca2+] of 1 mM, oCOm-21  
(1 μM) produced a small but significant increase in systolic intracellular Fluo-4 fluorescence 
(Figure 11A). Increasing the oCOm-21 concentration beyond 1 μM however, did not produce 
any statistical differences in the F/F0 ratio (Figure 11A), where F and F0 are the fluorescence 
produced due to oCOm-21 treatment and baseline (in the absence of oCOm-21), respectively. 
oCOm-21 administration (1 – 10 μM) in the presence of a higher extracellular [Ca2+] (2 and  
4 mM) did not produce statistical increases in the F/F0 ratio (Figure 11B and 11C). 
 
Figure 11. Isolated rat cardiomyocytes exposed to oCOm-21 in a fixed extracellular [Ca2+]. 
Isolated rat cardiomyocytes were treated in a concentration-response manner with oCOm-21 (1 
– 10 μM) at fixed extracellular [Ca2+]: A) 1 mM Ca2+ (n = 3); B) 2 mM (n = 3) and C) 4 mM 
Ca2+ (n = 2). Bars represent mean ± SEM and was analysed using a one-way repeated measures 
ANOVA with a Bonferroni post hoc test. *Statistically significant difference compared to 0 μM 
oCOm-21 treatment, p ≤ 0.05. 
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Rearrangement of the data presented in Figure 11 produced a [Ca2+]-response curve where 
increased extracellular Ca2+ was in the presence of an individual oCOm-21 concentration  
(1 – 10 μM) (Figure 12). Increasing oCOm-21 concentrations did not increase the F/F0 ratio 
responses produced by increasing extracellular [Ca2+] when compared to the untreated 
cardiomyocytes (Figure 12). 

























Figure 12. Isolated rat cardiomyocytes at a fixed oCOm-21 concentration but varying 
extracellular [Ca2+]. Datum from Figure 11 was rearranged into a [Ca2+]-response curve per 
oCOm-21 concentration (●, 0 μM; ■, 1 μM; ▲, 3 μM; ▼, 10 μM) (n = 3 at 1 and 2 mM Ca
2+; 




4.6 Impact of oCOm-21 on the Number of Spontaneous Cardiomyocyte Contractions 
oCOm-21 (0 – 10 μM) had no impact on the number of spontaneous contractions provoked in 
the isolated rat cardiomyocytes exposed to increasing concentrations of extracellular [Ca2+]  
(1 – 4 mM) (Figure 13A – 13C). 
 
Figure 13. Number of spontaneous contractions recorded in isolated rat cardiomyocytes 
following oCOm-21 treatment. Isolated rat cardiomyocytes were treated in a concentration-
response manner with oCOm-21 (0 – 10 μM) in a fixed extracellular [Ca2+]: A) 1 mM (n = 3); 
B) 2 mM (n = 3) and C) 4 mM (n = 2). The number of spontaneous contractions elicited was 
recorded in a 2-minute period following the cessation of electrical pacing. Bars represent mean 
± SEM and was analysed using a one-way repeated measures ANOVA. 
  



































































































B A C 
39 
Organisation of the data in Figure 13 from an oCOm-21 concentration-response curve to a 
[Ca2+]-response curve provided an insight to whether an increasing extracellular [Ca2+] 
increased the number of spontaneous contractions at a given, fixed oCOm-21 concentration 
(Figure 14). Changes in extracellular [Ca2+] at any given oCOm-21 concentration (0 – 10 μM) 
did not increase the number of spontaneous contractions exhibited in isolated rat 
cardiomyocytes (Figure 14). 






































Figure 14. Number of spontaneous contractions within a fixed oCOm-21 concentration 
but varying extracellular [Ca2+]. Datum from Figure 13 was rearranged in to a [Ca2+]-
response curve per oCOm-21 concentration (●, 0 μM; ■, 1 μM; ▲, 3 μM; ▼, 10 μM) (n = 3 at 
1 and 2 mM Ca2+; n = 2 at 4 mM Ca2+). Data are represented as mean ± SEM and was analysed 
using a two-way ANOVA. 
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4.7 Impact of oCOm-21 on H2O2 Generation in Human Cardiomyocyte AC16 Cells 
To determine whether oCOm-21 infusion increased intracellular ROS production, cells were 
loaded with the fluorescent probe H2DCF-DA. Validation of the H2DCF-DA assay in AC16 
cells was confirmed using exogenous H2O2 over a 20-minute period. A time and concentration-
dependent increase in H2DCF-DA fluorescence was observed with H2O2 (10 and 100 μM) when 
compared to the untreated controls (Figure 15). Although both oCOm-21 (0.1 – 100 μM) and 
BP-21 (0.1 – 100 μM) produced a time-dependent increase in fluorescence at all concentrations, 
this was found to not be significant (Figure 16 and 17). Furthermore, a concentration-dependent 
effect with oCOm-21 and BP-21 was not was not exhibited (Figure 16 and 17). 




























Figure 15. Validation of the H2DCF-DA Assay in AC16 Cells. Intracellular ROS content in 
AC16 cardiomyocytes treated with H2O2 was determined using the H2DCF-DA fluorophore. 
AC16 cardiomyocyte cells were loaded with H2DCF-DA (100 μM) and were either untreated 
controls (●) or treated with H2O2
 (■, 1 μM; ▲, 10 μM or ▼, 100 μM) (n = 3 for all treatment 
groups in triplicate). Data are represented as mean ± SEM and was analysed using a two-way 
repeated measures ANOVA with a Bonferroni post hoc test. *Significant difference compared 
to control at the same time point, p ≤ 0.05. 
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Figure 16. Determination of intracellular ROS production with oCOm-21. AC16 cardiomyocytes were loaded with the fluorophore H2DCF-DA 
(100 μM) and were either untreated controls (●) or treated with oCOm-21 (■, 0.1 μM; ▲, 0.3 μM; ▼, 1 μM; ♦, 3 μM; ●, 10 μM; ■, 30 μM or  




































Figure 17. Determination of intracellular ROS production with BP-21. AC16 cardiomyocytes were loaded with the fluorophore H2DCF-DA (100 
μM) and were either untreated controls (●) or treated with BP-21 (■, 0.1 μM; ▲, 0.3 μM; ▼, 1 μM; ♦, 3 μM; ●, 10 μM; ■, 30 μM or ▲100 μM) (n = 3 







4.8 oCOm-21 Mediated Intracellular NO Production with H2DAF-FM DA 
To determine whether oCOm-21 increased intracellular NO production the intracellular 
fluorescent probe H2DAF-FM DA was used. Validation of the H2DAF-FM DA assay was 
performed using sodium nitroprusside (SNP, 1 – 10 mM), a positive control, and trialled with 
oCOm-21 (100 μM) (Figure 18). Both SNP and oCOm-21 produced a time-dependent increase 
in H2DAF-FM DA fluorescence though this was not significant when compared to the control 
at various cell densities (10,000 – 50,000 cells per well, respectively) (Figure 18A – 18D). 
 
Figure 18. Determination of intracellular NO content with H2DAF-FM DA. AC16 
cardiomyocyte cells were seeded at A) 10,000; B) 20,000; C) 40,000 and D) 50,000 cells per 
well and were loaded with the fluorophore H2DAF-FM DA (2 μM). Cells were then allocated 
to untreated control (●), sodium nitroprusside (SNP; ▼, 1 mM or ▲, 10 mM) or oCOm-21  
(■, 100 μM) (n =2 for all treatment groups at each cell density in triplicate). Data are represented 













































































4.9 Spin Trapping with CPTIO 
Preliminary investigations were performed with the spin trap, CPTIO, to determine the minimal 
detectable sensitivity of NO released by PAPA NONOate and the stability of the CPTIO-NO 
complex once it was formed (Figures 19 – 22). In the absence of NO, CPTIO produces an EPR 
absorbance spectrum with five lines with a relative intensity of 1: 2: 3: 2: 1. When CPTIO-NO 
is formed, a new line appears between lines which can then go on to be quantified to determine 
the NO content present (Kleschyov et al., 2007). 
Initial characterisation of the sensitivity of this spin trap was performed by incubating CPTIO 
(100 μM) with various concentrations of PAPA NONOate (0.1 – 100 μM) (Figure 19A, 19B 
and 24A). The EPR spectra of the formed CPTIO-NO complex was then measured after 15-
minutes which coincided with the half-life of PAPA NONOate (t1/2 = 15-minutes) so that the 
amount of NO released could be accurately quantified. As PAPA NONOate releases two 
molecules of NO, the amount of NO released after the first half-life coincides with the 
concentration of PAPA NONOate used e.g. 1 μM PAPA NONOate releases 1 μM NO. CPTIO 
(100 μM) produced a concentration-dependent increase in peak signal height with increasing 
concentrations of PAPA NONOate (0.1 – 100 μM) (Figure 19A, Figure 19B and 24A). The 
CPTIO-NO complex appeared to have the sensitivity to detect 20 μM NO released from 20 μM 
PAPA NONOate as a minor peak and trough was observed (Figure 19A, 19B, 24A). The 
CPTIO-NO signal then saturated at 60 μM PAPA NONOate as any further increases in PAPA 
NONOate concentration exhibited a decrease in the peak signal height (Figure 19 and 24A). 
To determine the kinetic stability of the CPTIO-NO complex formed, CPTIO (100 μM) was 
incubated with PAPA NONOate (100 μM) and the EPR spectrum was recorded over a one-
hour period (Figure 20A, 20B and 24B). The CPTIO-NO signal developed over-time between 
0 – 30-minutes and plateaued from 30-minutes onwards (Figure 20A, 20B and 24B). The 
stability of CPTIO-NO was then further tested to examine whether the complex formed could 
retain a refined signal for an extended period of time which lasted for 24 hours (Figure 21, 22 
and 24C). CPTIO had an initial detectable sensitivity for 10 μM PAPA NONOate (Figure 21) 
though this sensitivity was lost and became more ambiguous by the end of 24 hours (Figure 
22), indicating that the detection of small quantities of NO had to be performed relatively 
immediate. 
Treating AC16 cells with oCOm-21 (10 – 100 μM) in the presence of CPTIO (100 μM) over a 
1-hour period (Figure 23 and 24D) produced no distinct peak or trough that was distinguishable 
to the untreated control. 
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Figure 19. Sensitivity characterisation of CPTIO. A) CPTIO (100 μM) was mixed with varying concentrations of PAPA NONOate (■, 0.1 μM;  
■, 20 μM; ■, 40 μM; ■, 60 μM; ■, 80 μM; ■, 100 μM) in PBS and the EPR was recorded at the end of 15-minutes in the following conditions: X-band; 
magnetic field strength, 335 – 340 mT; sweep time, 150 s; modulation, 0.8 mT; accumulations, 1; microwave power, 1 and temperature, 293 – 296 K 
(20 – 23 °C). B) A magnification of the selected area in A). Using the 60 μM PAPA NONOate CPTIO EPR spectrum as an example, the numbers indicate 




■ 100 μM PAPA NONOate 
■ 80 μM PAPA NONOate 
■ 60 μM PAPA NONOate 
■ 40 μM PAPA NONOate 
■ 20 μM PAPA NONOate 
■ 0.1 μM PAPA NONOate 
■ 100 μM PAPA NONOate 
■ 80 μM PAPA NONOate 
■ 60 μM PAPA NONOate 
■ 40 μM PAPA NONOate 
■ 20 μM PAPA NONOate 










Figure 20. Kinetic characterisation of CPTIO over 60-minutes. A) CPTIO (100 μM) was mixed with PAPA NONOate (100 μM) in PBS and the EPR 
spectrum was recorded every 10-minutes for 60-minutes in the following conditions: X-band; magnetic field strength, 335 – 340 mT; sweep time, 300 
s; modulation, 0.8 mT; accumulations, 1; microwave power, 1 and temperature, 293 – 296 K (20 – 23 °C). B) A magnification of the selected area in A). 
Lines indicate the time the read was taken in minutes (■, 0-minutes; ■, 10-minutes; ■, 20-minutes; ■, 30-minutes; ■, 40-minutes; ■, 50-minutes; 

























Figure 21. Kinetic characterisation of CPTIO 
over 24-hours – initial read. A) CPTIO (100 μM) 
was mixed with PAPA NONOate (■, 0 μM control; 
■, 100 μM; ■, 50 μM; ■, 25 μM; ■, 10 μM) in PBS 
and the EPR spectrum was recorded at the end of 
15-minutes in the following conditions: X-band; 
magnetic field strength, 335 – 340 mT; sweep time, 
150 s; modulation, 0.8 mT; accumulations, 1; 
microwave power, 1 and temperature, 293 – 296 K 
(20 – 23 °C). B) A magnification of the selected 







■ 100 μM PAPA NONOate 
■ 50 μM PAPA NONOate 
■ 25 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 0 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 0 μM PAPA NONOate 
 
■ 100 μM PAPA NONOate 
■ 50 μM PAPA NONOate 
■ 25 μM PAPA NONOate 
■ 10 μM PAPA NONOate 






Figure 22. Kinetic characterisation of CPTIO 
over 24-hours – final read. A) CPTIO (100 μM) 
was mixed with PAPA NONOate (■, 0 μM control; 
■, 100 μM; ■, 50 μM; ■, 25 μM; ■, 10 μM) in PBS 
and the EPR spectrum was recorded after 24 hours 
following the initial reading in Figure 15 in the 
following conditions: X-band; magnetic field 
strength, 335 – 340 mT; sweep time, 150 s; 
modulation, 0.8 mT; accumulations, 1; microwave 
power, 1 and temperature, 293 – 296 K (20 – 23 °C). 
B) A magnification of the selected area in A).  







■ 100 μM PAPA NONOate 
■ 50 μM PAPA NONOate 
■ 25 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 0 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 0 μM PAPA NONOate 
 
■ 100 μM PAPA NONOate 
■ 50 μM PAPA NONOate 
■ 25 μM PAPA NONOate 
■ 10 μM PAPA NONOate 







Figure 23. CPTIO in AC16 cells treated with oCOm-21. A) 2 x 106 cells were either untreated controls (■) or treated with oCOm-21 (■, 10 μM;  
■ 100 μM) in PBS in the presence of CPTIO (100 μM). The medium containing the spin trap was then extracted and the EPR spectrum was recorded at 
the end of 1 hour of treatment in the following conditions: X-band; magnetic field strength, 335 – 340 mT; sweep time, 150 s; modulation, 0.8 mT; 




■ 100 μM oCOm-21 
■ 10 μM oCOm-21 
■ 0 μM oCOm-21 
■ 100 μM oCOm-21 
■ 10 μM oCOm-21 







Figure 24. Determination of the characteristics of the CPTIO-NO complex. A) CPTIO (100 
μM) was mixed with increasing concentrations of PAPA NONOate (0.1 – 100 μM) (Figure 19) 
and the EPR signal height between was recorded at the magnetic field strength 336.9 - 337.1 
mT or g ≈ 2.008 – 2.006. B) CPTIO (100 μM) in the presence of PAPA NONOate (100 μM) 
was recorded over time to develop a kinetic profile (Figure 20). EPR signal height was then 
noted at the magnetic field strength 336.9 – 337.1 mT or g ≈ 2.008 – 2.006. C) Stability of the 
CPTIO-NO complex when CPTIO (100 μM) in the presence of PAPA NONOate (100 μM) was 
performed by measuring the peak EPR signal height at the magnetic field strength 336.7 – 336.9 
mT or g ≈ 2.008 – 2.006 at time = 0 hours (initial read, ●) and 24 hours after (final read, ■) 
(Figures 21 and 22, respectively). D) Quantification of the peak EPR signal height of the 
CPTIO-NO formed when AC16 cells were untreated controls or treated with oCOm-21 (10 - 
100 μM) (Figure 23) at the magnetic field strength 336.8 – 337.0 mT or g ≈ 2.007 – 2.006. 
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4.10 Spin Trapping with Fe(DETC)2 
Continued investigation on whether oCOm-21 increased intracellular NO was performed using 
the spin trap probe Fe(DETC)2. Fe(DETC)2 binds to NO in a 1: 1 stoichiometric ratio and when 
bound, produces a hyperfine triplet structure as indicated in Figure 25 (Kleschyov et al., 2007). 
To determine the detectable sensitivity of Fe(DETC)2, Fe(DETC)2 (1 mM) was incubated with 
PAPA NONOate (1 – 10 μM) for 15-minutes (Figure 25). The Fe(DETC)2-NO product formed 
displayed an EPR spectrum with a distinct hyperfine, triplet structure that increased in 
amplitude with increasing PAPA NONOate concentration (1 – 10 μM) at 293 – 296 K (20 –  
23 °C) (Figure 25 and 31A). The inability to consistently detect NO released from 1 μM PAPA 
NONOate, indicated that the protocol used to create the spin trap and measure the Fe(DETC)2-
NO signal needed to be further optimised. This involved: 1) the addition of BSA (10 mg/mL) 
when the spin trap was made to prevent the precipitation and oxidation of Fe2+; 2) performance 
of an ethyl acetate organic solvent extraction to concentrate the Fe(DETC)2-NO signal and  
3) measurement of the Fe(DETC)2-NO signal at 173 K (
-100 °C) to stabilise the product formed 
(Figure 26). The implementation of all three aspects resulted in the consistent ability to detect 
as low as 10 μM PAPA NONOate which correlated to 10 μM NO (Figure 26 and 31B). 
To prevent the diffusion of NO out of solution, performance of an ethyl acetate extraction 
concentrated any formed Fe(DETC)2 above the reaction mixture prior to the addition of PAPA 
NONOate. This initially did not provide any improvement in the detectable sensitivity of the 
spin trap below 100 μM PAPA NONOate or 100 μM NO after 15-minutes when the 
Fe(DETC)2-NO EPR spectrum was recorded at 293 – 296 K (20 – 23 °C) (Figure 27A and 
31C). Decreasing the temperature down to 173 K (-100 °C) resulted in a detectable sensitivity 
of roughly 10 μM NO released from 10 μM PAPA NONOate (Figure 28 and 31D) as a distinct, 
triplet structure was present. However, prior formation of the Fe(DETC)2-ethyl acetate layer 
was not performed in the following studies involving the measurement of NO in AC16 cells 
incubated with oCOm-21. This was because of the observed decrease in the magnitude of the 
peak signal height and hence, sensitivity, when compared to the prior protocol where an ethyl 
acetate extraction was performed at the end of incubation period with Fe(DETC)2 and PAPA 
NONOate (Figure 26, 28, 31B and 31D). 
Measurement of the Fe(DETC)2-NO EPR spectrum at 173 K (
-100 °C) from cells treated with 
or without oCOm-21 (100 μM) (Figure 29 and 31E) in the presence of BSA (10 mg/mL), failed 
to exhibit a distinct signal in either the supernatant (processed further with an ethyl acetate 
extraction) or the cell suspension. With an increased cell count from 8.8 x 106 to 17.6 x 106 
52 
cells (Figure 30 and 31F), the Fe(DETC)2 signal was prepared and recorded utilising the same 
parameters, i.e. in the presence of BSA (10 mg/mL) and the EPR absorbance spectrum recorded 
at 173 K (-100 °C), respectively. However, increasing the cell count produced similar findings 
where no distinct Fe(DETC)2 EPR spectrum at 173 K (
-100 °C) was observed in either the 
supernatant (again, processed with ethyl acetate) or the cell suspension treated with or without 
oCOm-21 (100 μM) (Figure 30 and 31F). Notably, a Fe(DETC)2-NO absorbance spectrum at 
173 K (-100 °C) was able to be obtained with 10 μM PAPA NONOate prepared with BSA (10 




Figure 25. Sensitivity characterisation of the spin trap Fe(DETC)2. Fe(DETC)2 (1 mM) mixed with PAPA NONOate (■, 1 μM or ■, 10 μM) in PBS 
and the EPR spectrum was recorded after 15-minutes of incubation in the following conditions: X-band; magnetic field strength, 326 – 338 mT; sweep 
time, 60 s; modulation, 0.2 mT; accumulations, 5; microwave power, 50 and temperature, 293 – 296 K (20 – 23 °C). Using the 10 μM PAPA NONOate 
EPR absorbance spectrum as an example, 1 – 3 indicate the hyperfine, triplet structure when Fe(DETC)2-NO is present. 
  
■ 10 μM PAPA NONOate 











Figure 26. Optimisation of the sensitivity of Fe(DETC)2. A) Fe(DETC)2 (1 mM) mixed with BSA (10 mg/mL) and PAPA NONOate (■, 100 nM;  
■, 1 μM; ■, 10 μM; ■, 100 μM) in PBS. Following a 15-minute incubation, Fe(DETC)2 was extracted with ethyl acetate and the EPR spectrum of the 
organic layer was recorded in the following conditions: X-band; magnetic field strength, 326 – 338 mT; sweep time, 60 s; modulation, 0.2 mT; 
accumulations, 5; microwave power, 50 and temperature, 173 K (-100 °C). B) A magnification of the selected area in A) with the absence of the 




■ 100 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate  
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 
■ 1 nM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate 
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 







Figure 27. Sensitivity of Fe(DETC)2 through prior ethyl acetate extraction and room temperature read. A) Fe(DETC)2 (1 mM) mixed with BSA  
(10 mg/mL) in PBS was immediately extracted with ethyl acetate with the resulting inorganic phase being treated with PAPA NONOAate (■, 100 μM; 
■, 10 μM; ■, 1 μM; ■, 100 nM; ■, 10 nM; ■, 1 nM). The EPR of the organic layer was then recorded under the following conditions: X-band; magnetic 
field strength, 326 – 338 mT; sweep time, 60 s; modulation, 0.2 mT; accumulations, 5; microwave power, 50 and temperature, 293-296 K (20 – 23 °C). 




■ 100 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate 
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 
■ 1 nM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate 
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 







Figure 28. Sensitivity of Fe(DETC)2 through prior ethyl acetate layer extraction at 173 K. A) Fe(DETC)2 (1 mM) mixed with BSA (10 mg/mL) in 
PBS was immediately extracted with ethyl acetate with the resulting inorganic phase being treated with PAPA NONOate (■, 100 μM; ■, 10 μM;  
■, 1 μM; ■, 100 nM; ■, 10 nM; ■, 1 nM). The EPR of the organic layer was then recorded under the following conditions: X-band; magnetic field 
strength, 326 – 338 mT; sweep time, 60 s; modulation, 0.2 mT; accumulations, 5; microwave power, 50 and temperature, 173 K (-100 °C). B) A 




■ 100 μM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate 
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 
■ 1 nM PAPA NONOate 
■ 10 μM PAPA NONOate 
■ 1 μM PAPA NONOate 
■ 100 nM PAPA NONOate 
■ 10 nM PAPA NONOate 







Figure 29. Fe(DETC)2-NO in AC16 cells treated with oCOm-21. Fe(DETC)2 (1 mM) was prepared with BSA (10 mg/mL) in PBS and added to PAPA 
NONOate (10 μM) or AC16 cells (total cell count of 8.8 x 106) treated without or with oCOm-21 (100 μM) for 15 or 20-minutes, respectively, at 310 K 
(37°C). Following incubation ethyl acetate extraction was performed and the resulting organic layer or cell suspension was recorded in the following 
conditions: X-band; magnetic field strength, 326 – 338 mT; sweep time, 60 s; modulation, 0.2 mT; accumulations, 5; microwave power, 50 and 
temperature, 173 K (-100 °C). Spin trap in the presence of PAPA NONOate (■, 10 μM), untreated cells (■, the organic layer; ■, the cell suspension) or 
oCOm-21 treated cells (■, the organic layer treated with 100 μM oCOm-21; ■, the cell suspension treated with 100 μM oCOm-21). 
  
■ 10 μM PAPA NONOate 
■ Untreated cells, organic layer 
■ Untreated cells, cell suspension 
■ oCOm-21 treated cells, organic layer 







Figure 30. Fe(DETC)2-NO in AC16 cells treated with oCOm-21 - an increased cell count. Fe(DETC)2 (1 mM) was prepared with BSA (10 mg/mL) 
in PBS and added to PAPA NONOate (10 μM) or AC16 cells (total cell count of 17.6 x 106) treated without or with oCOm-21 (100 μM) for 15 or 20-
minutes, respectively, at 310 K (37°C). Ethyl acetate extraction was performed and the resulting organic layer or cell suspension was recorded in the 
following conditions: X-band; magnetic field strength, 326 – 338 mT; sweep time, 60 s; modulation, 0.2 mT; accumulations, 5; microwave power, 50 
and temperature, 173 K (-100 °C). Spin trap in the presence of PAPA NONOate (■, 10 μM), untreated cells (■, the organic layer; ■, the cell suspension) 
or oCOm-21 treated cells (■, the organic layer treated with 100 μM oCOm-21; ■, the cell suspension treated with 100 μM oCOm-21). 
 
■ 10 μM PAPA NONOate 
■ Untreated cells, organic layer 
■ Untreated cells, cell suspension 
■ oCOm-21 treated cells, organic layer 








Figure 31. Determination of the characteristics of the Fe(DETC)2 complex. A) Fe(DETC)2 
(1 mM) was mixed with PAPA NONOate (1 – 10 μM) and the EPR signal height was quantified 
at the magnetic field strength 330.8 – 331.7 mT or g ≈ 2.05 – 2.04 (Figure 25). B) BSA (10 
mg/mL) was added to Fe(DETC)2 (1 mM) with PAPA NONOate (100 nM – 100 μM). The 
formed Fe(DETC)2-NO complex was then extracted with ethyl acetate and the formed peak 
EPR signal height was measured at the magnetic field strength 330.8 – 331.6 mT or g ≈ 2.05 – 
2.04 (Figure 26). C) and D) Ethyl acetate extraction was performed following Fe(DETC)2  
(1 mM) in BSA (10 mg/mL) formation prior to PAPA NONOate (100 nM – 100 μM) addition 
to the inorganic layer. Peak EPR signal height of the organic ethyl acetate layer was then 
recorded at the magnetic field strength 330.3– 331.6 mT or g ≈ 2.05 – 2.04 at 293 – 296 K (20 
– 23 °C) or 173 K (-100 °C), respectively (Figures 27 and 28, respectively). E) Fe(DETC)2 (1 
mM) with BSA (10 mg/mL) in the presence of PAPA NONOate (10 μM) or with AC16 cells 
(8.8 x 106) treated with oCOm-21 (100 μM) underwent ethyl acetate extraction and the peak 
EPR signal height was recorded at the magnetic field strength 330.9 – 331.6 mT or g ≈ 2.05 – 
2.04. OL, organic layer. CS, cell suspension (Figure 29). F) Repetition of the protocol in Figure 
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4.11 Concentration-response Curves of Individual Human Atrial Trabecula Treated with 
oCOm-21 
Examination of the developed force traces in trabecula treated in a concentration-response 
manner with oCOm-21 (0.1 – 10 μM) (Figure 32) showed patient differences in responsiveness. 
While some patient samples exhibited an inotropic response, arbitrarily defined as a 10% or 
1.1-fold increase in developed force when compared to baseline, other patient samples failed to 
respond or deteriorated rapidly over the protocol period. Trabecula exhibiting an inotropic 
effect due to oCOm-21 (0.1 – 10 μM) infusion also appeared to not produce an apparent or 
consistent trend with change in the developed force. Trabecula originating from patients 666, 
669 and 679 produced a biphasic concentration-response curve. Trabecula from 735, 736 and 
787 displayed a more plateaued development in force generated and beyond 1 μM oCOm-21 
infusion, developed force rapidly declined. Conversely, trabecula originating from patients 690 
and 755 exhibited a more abrupt and sustained increase in developed force inclusive of and 
beyond 3 μM oCOm-21 (Figure 32). Remaining trabecula provided gradually decreasing 
developed forces with increasing concentrations of oCOm-21 (0.1 – 10 μM), failing to increase 























































Figure 32. Individual traces of human atrial trabecula tissue treated with oCOm-21. Atrial 
tissue was treated in a concentration-response manner with oCOm-21 (0.1 – 10 μM) until a 
concentration-response curve was generated (n = 19). 
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4.12 Summation of oCOm-21 Mediated Inotropy in Human Atrial Trabecula 
Treatment of trabecula originating from the right atrial appendage with oCOm-21 in a 
concentration-response manner produced a biphasic concentration-response curve with regard 
to change in the mean developed force (Figure 33A). However, when the median is considered, 
the developed force decreases with increasing oCOm-21 concentration (Figure 33B). Although 
there was increasing variability in the developed force produced with increasing oCOm-21 
concentration, a statistically significant decrease was observed when 10 μM is compared to 0.1, 
0.2 and 1 μM oCOm-21 using a non-parametric Friedman ANOVA with a Dunn’s post hoc test 
(Figure 33A and 33B). 
 
Figure 33. Summative findings of oCOm-21 mediated inotropy in human atrial trabecula 
tissue. Atrial trabeculae were treated in a concentration-response manner with oCOm-21  
(□, 0.1 – 10 μM) (n = 19). A) Points mean ± SEM and B) as a box and whisker plot with the 
maximum, 75% quartile, median, 25% quartile and minimum. Data was analysed using a non-
parametric Friedman ANOVA with a Dunn’s post hoc test. *Significant 0.1 μM and 10 μM 
oCOm-21 comparison, p ≤ 0.05. +Significant 0.2 μM and 10 μM oCOm-21 comparison,  
























































































4.13 Differential Patient Characteristics Between Responders and Non-responders 
Patient characteristics of trabecula were categorised into responders or non-responders based 
on whether the trabecula produced an inotropic effect (defined as an equal to or greater than 
1.1-fold increase in the developed force when compared to its respective baseline) at any given 
oCOm-21 concentration (0.1 – 10 μM) (Figure 34). Of the patient characteristics examined, 
only bodyweight and body surface area (using both the Dubois and Dubois and Mosteller 
calculation) produced a significant comparison, where in which the responders had a higher 
bodyweight and surface area when compared to the non-responding group (Figure 34A – 34C). 
 
Figure 34. Differential patient characteristics between responders and non-responders. 
Atrial trabecula and subsequent corresponding patient characteristics A) body weight and body 
surface area using either the B) Dubois and Dubois or C) Mosteller equation was separated into 
responders (●, n = 8) and non-responders (■, n = 11) based on whether an inotropic effect was 
observed with oCOm-21 (0.1 – 10 μM) infusion (Figure 32). Bars represent mean ± SEM and 
data was analysed using a non-parametic Mann-Whitney t-test. *Statistically significant 




















































































4.14 Differential Echocardiographic Data Between Responders and Non-responders 
With regards to the echocardiographic data, trabecula that responded to oCOm-21 by producing 
an inotropic effect originated from hearts that only had a significantly lower left ventricular 
poster wall thickness during diastole (LVPWd) but higher right atrial area and right atrial end 
systolic volume when compared to the non-responding group (Figure 35A – 35C). 
 
Figure 35. Differential right atrial parameters between responders and non-responders. 
Atrial trabecula and subsequent corresponding patient echocardiography data A) left ventricular 
poster wall thickness during diastole (LVPWd); B) right atrial area and C) right atrial end 
systolic volume was separated into responders (●, n = 8) and non-responders (■, n = 11) based 
on whether an inotropic effect was observed with oCOm-21 (0.1 – 10 μM) infusion (Figure 32). 
Bars represent mean ± SEM and data was analysed using a non-parametric Mann-Whitney t-













































































4.15 Comparison of Haemodynamics Between Responders and Non-responders 
Haemodynamic parameters of trabeculae were divided into the two groups, responders or non-
responders, based on whether an inotropic effect was observed due to oCOm-21 infusion. 
Developed force within the responders group increased in a concentration-dependent manner 
but was only found to be significantly increased when compared to equivalent concentrations 
of oCOm-21 infusion in the non-responders group (Figure 36A). Conversely, the non-responder 
group exhibited a divergent, concentration-dependent decrease in developed force with 
increasing concentration of oCOm-21 (0.1 - 10 μM) (Figure 36A). 
Both dF/dTmax and dF/dTmin (Figure 36B and 36C) exhibited diverging concentration-
dependent effects when trabeculae were separated into the responder and non-responder groups 
due to oCOm-21 infusion. However, only 0.2 μM oCOm-21 produced a significant increase in 
dP/dTmin when compared to 0.1 μM oCOm-21 within the responder group (Figure 36B). In the 
non-responder group, oCOm-21 diminished both dF/dTmax and dF/dTmin (Figure 36B and 36C) 
in a concentration-dependent manner as responses were significantly different to 0.1 μM 
oCOm-21. 
Examination of tau (Figure 36D) between the responders and non-responders failed to produce 
a group effect or a concentration-dependent difference. This occurred despite the fact that tau 
appeared to increase in the non-responder group with increasing oCOm-21 concentration (0.1 





Figure 36. Comparison of haemodynamic parameters between responders and non-
responders. Atrial trabecula treated in a concentration-response manner with oCOm-21 (0.1 – 
10 μM) were divided into their respective responders (●, n = 8) and non-responders (♦, n = 11) 
subgroups. Haemodynamic parameters: A) developed force; B) peak rate of force development 
to systole (dF/dTmax); C) peak rate of force decline to diastole (dF/dTmin) and D) tau were 
monitored. Data are represented as mean ± SEM and was analysed using a two-way ANOVA 
with a Bonferroni post hoc test. *Statistically significant comparison between responders and 
non-responders at the same concentration, p ≤ 0.05. xStatistically significant comparison 
between the indicated oCOm-21 concentration and 0.1 μM oCOm-21 within the non-
responding group, p ≤ 0.05. +Statistically significant comparison between the indicated oCOm-













































































































































4.16 Comparison of Trabecula CSA Between Responders and Non-responders 
Responding trabecula which displayed an inotropic effect due to oCOm-21 infusion did not 


























Figure 37. Comparison of trabecula cross sectional area between responders and non-
responders. Atrial trabecula treated in a concentration-response manner with oCOm-21 (0.1 – 
10 μM) were divided into responders (●, n = 8) or non-responders (■, n = 11) based on whether 
an inotropic effect was observed during oCOm-21 infusion. Cross sectional area for each 
trabecula was then noted and divided based on this categorisation. Bars represent mean ± SEM 





This study confirmed that oCOm-21 has an inotropic action and elucidated a mechanism 
through which this effect may be achieved. Inotropy by oCOm-21 was achieved by the CO 
released from it and was not influenced or dependent on the benzene by-product produced. 
However, the observed inotropy by oCOm-21 appeared to be interrelated with NOS activity. 
Therefore, investigations on whether oCOm-21 induced S-nitrosylation, a common mechanism 
through which NO modulates intracellular proteins, on Ca2+ handling proteins was pursued. 
Ca2+ handling proteins within cardiomyocytes that modulate the inotropic state are known to 
be extremely susceptible to S-nitrosylation and thus, focus was placed on the SR Ca2+ gating 
channel, RyR2, due to the fact that: 1) CO specifically targets haem based proteins to produce 
a signalling effect, of which, nNOS, is one such protein; 2) nNOS co-immunoprecipitates with 
RyR2 indicating that there was an endogenous signalling pathway through which nNOS 
modulates RyR2 activity and 3) S-nitrosylation of RyR2 is inotropic (Lim et al., 2008; Thom 
et al., 2004; Xu et al., 1998). Attempts to determine RyR2 S-nitrosylation in rat myocardium 
was performed in the present study through western blotting though, was unsuccessful and 
hence, not shown in the current set of findings (Appendix 1). Insights into RyR2 gating 
properties through SOICR and examination of the number of spontaneous contractions 
suggested that oCOm-21 did not alter RyR2 release threshold. oCOm-21 in cardiomyocytes 
though, did increase the total amount of Ca2+ released from the SR at physiological but not 
supraphysiological extracellular [Ca2+]. 
The intended use of oCOms is as a clinical intervention for use in IR injury in patients 
undergoing cardiac surgery. To our knowledge, this is the first study to explore the application 
of CO at low concentrations in human cardiac tissue as a pharmacological agent. oCOm-21 
provided an inotropic response in a unique subset of tissues obtained from cardiomyopathy 
patients consented for CABG and/or atrial valve replacement surgery. 
5.1 Isolated Langendorff Perfused Hearts 
This study wanted to initially confirm whether: 1) the previously observed inotropic effect of 
oCOm-21 was reproducible and 2) to what extent oCOm-21 produced an inotropic effect. A 
ten-minute infusion period of oCOm-21 was implemented as previous work performed by our 
lab group established that this was the most effective duration to induce cardiac preconditioning 
(Adams et al., 2017; Chau et al., 2018). Characterisation of this inotropic response was 
performed by perfusing isolated hearts with a single concentration of oCOm-21 followed by a 
wash phase until a new steady state was achieved. A wash phase of 10-minutes was performed 
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in this study to minimise protocol time as viability concerns arose when hearts were perfused 
with a crystalloid buffer for an extended period beyond 2 – 3 hours. Inotropic responses due to 
oCOm-21 infusion appeared to be reversible as changes in haemodynamic parameters were 
reverted during the wash phase. 
This study showed that oCOm-21 produced a biphasic concentration-dependent response in the 
Langedorff perfused rat heart. A peak contraction was obtained with 3 µM oCOm-21. Changes 
in dP/dTmax and dP/dTmin due to oCOm-21 infusion were found to conform to the 
pharmacological response observed with developed pressure. This suggested that oCOm-21 
may elicit an inotropic effect by increasing the [Ca2+]i within the contractile myocardium 
through increased Ca2+ release from the SR along with an elevated rate of release and 
expulsion/reuptake of Ca2+ on a beat by beat basis. 
oCOm-21 did not induce a difference in heart rate compared to the response seen following 
infusion of the inactive by-product, BP-21. This finding negates the suggestion of a force-
frequency mediated effect as a plausible mechanism of oCOm-21 induced inotropy. A previous 
study examining CORM-3 in isolated Langendorff perfused hearts found that CO significantly 
decreased heart rate following a 10-minute infusion period (0.86-fold decrease compared to 
baseline) (Musameh et al., 2006). However, this finding may be due to the toxicity associated 
with the Ru core of the CORM-3 compound (Kueh et al., 2017). Much of the literature 
examining the impact of CO on heart rate focus on the clinical impact of toxic levels of CO 
accidently inhaled. CO poisoning has been clearly reported to induce tachycardia (Lee et al., 
2015; Satran et al., 2005). This toxic effect has been attributed to the inhibition of O2 transport 
due to the formation of COHb which manifests into ischaemia, myocardial dysfunction and 
consequent development of an atrioventricular block resulting in electrographic changes (Salih 
et al., 2013). 
Hearts infused with oCOm-21 also entered diastole for a longer period of time, indicated by an 
increase in tau, the time constant which represents the exponential decay of isovolumetric 
relaxation (Thomas et al., 1992). These findings suggested that oCOm-21 was lusitropic in 
nature and may modulate the activity of at least one aspect of Ca2+ handling during a cardiac 
cycle. It is important to note that alteration in one aspect of Ca2+ handling can result in several 
changes of other downstream Ca2+ handling proteins as the heart attempts to maintain 
homeostasis (Barry and Bridge, 1993; Carafoli, 1985). Therefore, the observed increase in tau 
should not just be solely attributed to the direct modulation of Ca2+ handling proteins typically 
associated with relaxation such as SERCA and NCX (Lipskaia et al., 2010). 
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Co-incubation of the perfused hearts with the non-isoform specific NOS inhibitor, L-NAME, 
significantly attenuated the haemodynamic responses to oCOm-21. Care was taken to ensure 
that the concentration of L-NAME (4 µM) applied did not impact on baseline haemodynamic 
beat to beat activity or coronary flow in these hearts (Kobara et al., 2003). NO is an essential 
component to maintaining excitation-contraction coupling, modulating Ca2+ handling proteins 
and mediating cardiac ion channels responsible for action potential generation (Khan et al., 
2003; Pacher et al., 2007; Tamargo et al., 2010). Interestingly, co-administration of oCOm-21 
with L-NAME increased heart rate in the present study. Literature suggests that L-NAME has 
the potential to increase heart rate. Andelova et al. (2005) showed that following a 15-minute 
infusion of L-NAME (100 μM), heart rate was significantly increased compared to the control 
group. The increase in heart rate by L-NAME combination infusion in this study may also be a 
compensatory mechanism to maintain cardiac output and subsequently, coronary flow rate as 
L-NAME (30 μM) has been indicated to significantly lower coronary flow in Wistar albino rat 
hearts (Zivkovic et al., 2013). 
The observed biphasic change in haemodynamic parameters due to oCOm-21 infusion could 
be explained by post-translational modifications of Ca2+ handling proteins. Ca2+/calmodulin-
dependent protein kinase II (CAMKII) phosphorylates RyR2 and S-nitrosylation of CAMKII 
is known to induce inotropy but, was not investigated in the present study due to the clear 
mechanistic rationale established for the haem-based, NO signalling pathway in the form of 
nNOS/RyR2 (Erickson et al., 2015). S-nitrosylation of RyR2 coincidently modulates cardiac 
function in a biphasic manner, where low levels of S-nitrosylation induces inotropy, while an 
abundance of S-nitrosylation on RyR2 irreversibly modifies the channel and impairs channel 
opening (Gonzalez et al., 2008). If oCOm-21 is a S-nitrosylating agent, modification of RyR2 
through S-nitrosylation is a plausible mechanism which may explain the observed biphasic 
inotropic effect. 
Undeniably, the contribution of the coronary vasculature in producing an inotropic effect must 
be considered when infusing CO. Vasodilation is known to induce inotropy through changes in 
coronary flow rate/pressure and CO is known to induce vasodilation through sGC (Downey, 
1997; Sammut et al., 1998). CO had also been previously shown to modulate NOS activity and 
this questioned whether CO induced sufficient NO production to result in a relevant 
physiological effect within cardiomyocytes (Tetreau et al., 1999; Yang et al., 2016). Findings 
from this study suggest that CO had a partial dependence on NO to induce an inotropic effect 
though whether this NO was predominantly acting in cardiomyocytes or endothelial cells was 
not determined. Findings in the present study indicate a change in the [Ca2+]i within 
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cardiomyocytes by oCOm-21 contributes to the observed inotropic effect. Kaczara et al. (2018) 
suggests an endothelial inotropic effect may also occur due to the upregulation of the pentose 
phosphate pathway by CO to increase NO production. This study also confirmed that CO was 
able to overcome NOS inhibition through L-NAME. L-NAME inhibits all isoforms of NOS 
though the contribution of iNOS was not considered in the present study. This was because 
iNOS is generally absent in cells not stimulated by cytokines (Luss et al., 1995). Furthermore, 
induction of iNOS was known to take longer than the infusion period of oCOm-21, where peak 
mRNA expression of iNOS was between 2 – 3 hours post-lipopolysaccharide induction (Sade 
et al., 1999). Explanation for the remaining contribution of the inotropic effect by CO are 
suggested to be sGC and NHE but not LTCC or PKCε-dependent (Musameh et al., 2006). 
Performance of additional concentration responses in isolated hearts infused with an inhibitor 
of sGC and NHE, 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one (ODQ) and 5-(N-ethyl-N-
isopropyl)amiloride (EIPA), respectively, along with perfusion of the hearts at a fixed coronary 
flow rate may resolve this issue. In response to these findings, follow up investigations of CO 
induced inotropy focused on cardiomyocytes Ca2+ handling in the absence of the endothelium. 
5.2 SOICR in RyR2/HEK293 Cells Treated with oCOm-21 
Use of a submaximal inotropic concentration of oCOm-21 was utilised to examine SOICR and 
hence, provide an insight into changes in RyR2 gating properties in RyR2/HEK293 cells. No 
change in the number of cells experiencing SOICR was exhibited, suggesting that oCOm-21 
did not modulate RyR2 release threshold or SERCA activity. However, an oCOm-21 
concentration-response curve should be performed to confirm this interpretation and determine 
whether changes in RyR2 gating or SERCA activity was causally linked to the observed 
inotropic effect in the isolated Langendorff hearts. Changes in RyR2 gating properties such as 
an increase in RyR2 release threshold would allow for a greater accumulation of Ca2+ inside 
the SR. Alternatively, decreasing the release threshold may result in a greater number of RyR2 
channels opening to release the SR stored Ca2+. Measurement of the amplitude or area under 
the curve (indicative of the [Ca2+]) during a SOICR event may provide an insight into whether 
oCOm-21 altered Ca2+ release and termination threshold. The present study only recorded the 
incidence of SOICR per [Ca2+]. Examination of the frequency of SOICR events per cell within 
a [Ca2+] may elucidate a SERCA-dependent effect due to oCOm-21 infusion. Interpretation of 
these findings though, suggested that low concentrations of CO released by oCOm-21 was not 
causally linked to Ca2+ triggered arrhythmias. 
Although HEK293 cells are neuronal in nature, nNOS expression has not been confirmed in the 
HEK293 cells used in the present study (Shaw et al., 2002). This limitation is noted as 
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progenitor HEK293 cells may lack endogenous nNOS expression. Alternatively, if nNOS is 
present, how it is expressed may impact whether nNOS is sufficiently adjacent to or complexed 
with RyR2 in the endoplasmic reticulum of this model. Incorrect orientation of nNOS with 
RyR2 would result in non-specific S-nitrosylation of RyR2 resulting in detrimental protein 
conformations associated with channel inactivity (Gonzalez et al., 2007; Gonzalez et al., 2008; 
Xu et al., 1998). Further research is needed with regards to determining what cysteine residues 
of RyR2 are essential for an inotropic effect to be observed. However, previous literature 
confirmed no nNOS or eNOS expression in wild-type HEK293 cells through western blotting 
(Eroglu et al., 2017). Because of this, examination of changes in [Ca2+]i due to oCOm-21 
infusion was pursued in isolated rat cardiomyocytes. 
5.3 Effect of oCOm-21 on [Ca2+]i in Isolated Ventricular Cardiomyocytes 
oCOm-21 only produced an increase in the systolic F/F0 in isolated cardiomyocytes at a 
physiological extracellular [Ca2+] (1 mM). For the F/F0 ratio to roughly rise by 10% due to 1 
μM oCOm-21 infusion is clinically relevant. During a cardiac contraction, the free [Ca2+]i 
during diastole is approximately 100 nM and dramatically increases to a peak concentration of 
1 μM during systole (Bers, 2000). Models of troponin-Ca2+ binding suggest that a complete, 
intact troponin complex has a Ca2+ binding constant, Kd, of 3 nM (Johnson et al., 1980). 
Therefore, for the peak systolic [Ca2+]i to increase by 10% indicates an additional 100 nM Ca
2+ 
that is released into the intracellular space which is 33 times the Kd of troponin binding to Ca
2+. 
Furthermore, for every free Ca2+ ion, approximately 100 – 200 are bound to Ca2+ buffers like 
SERCA and troponin C (Bers, 2001). This indicates a high probability that the majority of the 
increased Ca2+ released from the SR by oCOm-21 is bound to troponin C. Collectively, both 
the increased [Ca2+]i and high degree of binding between troponin C and Ca
2+ indicate that 
minute changes in [Ca2+]i can have a significantly profound effect on force development which 
may lead to an inotropic response. Unfortunately, further increases in oCOm-21 concentration 
at an extracellular [Ca2+] of 1 mM did not produce any additional significant findings. 
The inability to obtain further significant findings with increasing concentrations of oCOm-21, 
in particular, 3 μM, may in part be due to the small sample size. An n = 3 (i.e. 3 rats) was used 
for all parts of this study involving the examination of changes in intracellular Ca2+ content due 
to oCOm-21 infusion. Having a larger sample size may have had achieved a statistically 
relevant finding. Once achieved, this may have allowed for the correlation between changes in 
intracellular Ca2+ content and the concentration-response curve seen in the Langendorff 
perfused hearts infused with oCOm-21. Both the Langendorff data and Fluo-4 measurements 
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at an extracellular [Ca2+] of 1 mM in this study exhibited the trend of a biphasic concentration-
response curve. However, the two cannot be correlated together due to the lack of significance. 
Rearrangement of the oCOm-21 concentration-responses to a Ca2+-response curve provided an 
insight into RyR2 gating properties. A Ca2+-dependent effect on the F/F0 ratio within individual 
oCOm-21 concentrations was not present. The lack of a Ca2+-dependent effect in the present 
study is contrary to previous findings which suggest that a rise in cytosolic Ca2+ should be 
witnessed with increasing extracellular [Ca2+] (and be potentiated in the presence of an 
inotropic agent) (Frampton et al., 1991; Thandroyen et al., 1991). This is because increasing 
extracellular [Ca2+] increases RyR2 open probability (Chandrashekhar et al., 1999). 
Chandrashekhar et al. (1999), Frampton et al. (1991) and Thandroyen et al. (1991) all showed 
that isolated rat cardiomyocytes exhibited a positive correlation between increasing 
extracellular [Ca2+] (up to 10 mM) and intracellular Ca2+ transient amplitude. The present study 
may have had failed to find this positive correlation between intra and extracellular Ca2+ content 
due to the duration of the infusion protocol resulting in decreased viability over time. 
At a supraphysiological [Ca2+] (2 and 4 mM), oCOm-21 occasionally produced peak systolic 
F/F0 ratios equivalent to or greater than the caffeine peak. This suggested that oCOm-21 was 
able to release more Ca2+ from the SR than what the SR could store, which is not possible. 
Frampton et al. (1991) showed that with increasing extracellular [Ca2+] of up to 6 mM, the 
caffeine peak amplitude also increased i.e. that the SR stored and released more Ca2+. 
Furthermore, during perfusion of the desired extracellular [Ca2+], the amplitude of the Ca2+ 
transient never exceeded that of caffeine peak (Frampton et al., 1991). This indicates in the 
present study that either: 1) there was a delayed addition of caffeine, meaning that measurement 
of area under the curve may have had been a more appropriate method to quantify changes in 
[Ca2+]i compared to amplitude and/or 2) a cell viability issue was present in this study due to 
the extended oCOm-21 infusion protocol where changes in the transmembrane potential took 
place. Therefore, repetition of this protocol where isolated cardiomyocytes are only perfused 
with a single oCOm-21 concentration may produce a more consistent result and yield a 
significant, positive correlation between extracellular [Ca2+] and the F/F0 ratio. 
Confirmation of whether the observed inotropic effect was due to an increase in [Ca2+]i should 
be followed up by an examination of changes in myofilament Ca2+ sensitivity. Increased Ca2+ 
binding to myofilament proteins such as troponin C is associated with inotropy (MacGowan, 
2005). Preliminary investigation of changes in myofilament Ca2+ sensitivity could be performed 
by correlating changes in the F/F0 ratio with fractional shortening. The addition of a 
cardiomyocyte length module to the NIS software used or use of confocal microscopy to image 
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isolated cardiomyocytes at a higher resolution may allow for the quantification of fractional 
shortening (Williams et al., 1992). Further investigation of whether oCOm-21 altered 
myofilament Ca2+ sensitivity could be confirmed in mechanically or chemically skinned 
cardiomyocytes, where changes in the equilibrium constant Kd between troponin binding to 
Ca2+ would be examined (Chung et al., 2016). 
Notably, oCOm-21 consistently increased tau in a concentration-dependent manner in 
Langendorff perfused hearts, an increase in tau indicates a greater dissociation rate, koff, 
compared to the association rate, kon, decreasing the Kd of troponin-Ca
2+ binding (i.e. troponin 
binds with a higher affinity to Ca2+). This finding is supported by the literature as rats exposed 
to 250 ppm CO for 90-minutes were found to have increased maximal, Ca2+-activated, 
developed pressure, indicative of an increase in myofilament Ca2+ sensitivity and a decrease in 
Kd (Favory et al., 2006; Kusuoka et al., 1986). It is hypothesised that this finding by Favory et 
al. (2006) was due to changes in the cGMP/cAMP ratio (as CO induces sGC). Consequently, 
this resulted in an altered phosphorylation of sarcomeric proteins leading to an increased 
myofilament responsiveness to Ca2+ (de Tombe, 2003). Changes in myofilament Ca2+ 
sensitivity may also provide an explanation to the observed biphasic concentration response 
curve seen in hearts infused with oCOm-21. The initial increase in developed pressure was a 
result of a proportional increase in both the koff and kon though with increasing concentrations 
of oCOm-21, koff increased by a greater proportion than the koff resulting in reduced 
myofilament Ca2+ sensitivity and hence, a decrease in developed pressure. 
Insights into changes in RyR2 gating properties due to oCOm-21 infusion in isolated 
cardiomyocytes was performed by examining the number of spontaneous contractions in the 
absence of electrical stimuli. oCOm-21 did not significantly increase the number spontaneous 
contractions at any given extracellular [Ca2+] indicating that oCOm-21 was not proarrhythmic. 
This reinforced the findings found in the Langendorff perfused hearts where oCOm-21 was 
antiarrhythmic as heart rate was not significantly increased along with the oCOm-21-
RyR2/HEK293 cell studies as the number of SOICR events was not altered. However, 
elevations in myocyte Ca2+ concentration is a known mechanism to promote the development 
of arrhythmias and should be further investigated (Tisdale et al., 1995). Assessment of 
arrhythmogenesis with oCOm-21 could be performed by patch clamping isolated 
cardiomyocytes and/or the performance of echocardiography in vivo. High CO gas 
administration (100 μM – 1 mM) has been causally linked to prolongation of both atrial and 
ventricular action potentials (Abramochkin et al., 2011). This has been proven to be achieved 
by CO sustaining the inward Na+ current resulting in early after-depolarisation-like arrhythmias 
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and inhibition of the inward-rectifying K+ channel in isolated rat cardiomyocytes (Dallas et al., 
2012; Liang et al., 2014). Introduction of human recombinant Nav1.5, Kv1.5 and Cav1.2 (LTCC) 
ion channels in HEK293 cells also indicate further mechanisms through which CO can delay 
an action potential (Al-Owais et al., 2017; Elies et al., 2014; Scragg et al., 2008). Clinically, 
CO poisoning presents as disruption of cardiac repolarisation and elongation of the QT interval 
(Macmillan et al., 2001; Onvlee-Dekker et al., 2007; Sari et al., 2008). Therefore, whether any 
of these mentioned mechanisms are relevant to arrhythmogenesis with oCOm-21 infused hearts 
to needs to be confirmed. 
Future considerations with regards to oCOm-21 infusion in isolated rat cardiomyocytes would 
involve the implementation of a protocol to determine the supra maximal stimulating voltage. 
Cardiomyocyte viability decreased with increasing time during the experiment, indicating a 
change in the transmembrane potential. This resulted in several cardiomyocytes which 
exhibited an increase in the F/F0 ratio with the initial infusion of oCOm-21 that later failed to 
produce a complete concentration-response curve. Stimulating voltage was kept constant 
throughout this study and was not altered during the oCOm-21 infusion protocol as increasing 
stimulating voltage is known to increase the force of contraction (Gibbons and Fozzard, 1975). 
Therefore, alteration of this protocol where isolated cardiomyocytes are only infused with a 
single concentration of oCOm-21 followed by the addition of caffeine may negate this time-
dependent viability issue. 
5.4 Impact of oCOm-21 on ROS Formation 
Examination of changes in intracellular ROS due to oCOm-21 treatment was performed to 
determine its contribution to the mechanism of oCOm-21 mediated S-nitrosylation. Previous 
literature suggested that S-nitrosylation was readily established in the presence of an electron 
acceptor such as O2 or H2O2 (Gow et al., 1997). Alternative studies examining CO as a S-
nitrosylating agent provided an unclear conclusion as to whether basal ROS generation or CO 
mediated complex IV inhibition was essential for S-nitrosylation formation (Almeida et al., 
2015; Kaczara et al., 2018; Scragg et al., 2008). Using the fluorescent probe, H2DCF-DA, the 
present study revealed that neither oCOm-21 or BP-21 evoked ROS production. This opposes 
previous findings which proved that gaseous CO generates ROS and more specifically, 
increased H2DCF-DA fluorescence in a concentration-dependent manner (between 10 – 250 
μM) (Queiroga et al., 2011; Queiroga et al., 2010). However, a clarification should be made 
that H2DCF-DA can only be oxidised by H2O2 in the presence of Fe
2+ (Karlsson et al., 2010; 
McLennan and Degli Esposti, 2000). CO generates H2O2 by firstly inhibiting complex IV to 
produce O2
•– and it is through super oxide (SOD) that H2O2 is generated (Bilban et al., 2008). 
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Therefore, the use of H2DCF-DA was an indirect measure of CO mediated O2
•– production. If 
oCOm-21 acts as a S-nitrosylating agent, this study suggests that there was a sufficient number 
of electron acceptors through basal ROS production to form the post-translational modification. 
The inability to detect changes in ROS production by H2DCF-DA fluorescence may be due to: 
1) the antioxidant capacity of the cell through enzymes like SOD and glutathione (GSH); 2) an 
antioxidant potential of oCOm-21 or BP-21; 3) suppression of ROS formation; 4) inhibition of 
ROS interaction with the H2DCF-DA fluorophore and 5) the presence of transition metals 
which interact with ROS (or H2DCF-DA) which prevent oxidation of the dye. Addition of CO 
gas is known to upregulate the activity of antioxidant enzymes such as SOD and GSH (Chin et 
al., 2007; Zhang and Piantadosi, 1992). The cellular antioxidant capacity of AC16 cells 
however, has not been assessed. Therefore, SOD activity or quantification of the oxidised to 
reduced GSSH/GSH ratio with oCOm-21 treatment should be determined. This would indicate 
whether the oxidant burden was taken up by intracellular ROS scavenging mechanisms or 
oCOm-21/BP-21 treatment. Interestingly, both oCOm-21 and BP-21 present phenols as 
branching functional groups off of the CO-releasing motif and chemical compounds consisting 
of a phenol are known to exhibit an antioxidant potential (Bendary et al., 2013). This 
consequently indicates that oCOm-21/BP-21 may exhibit the potential to inhibit the 
transduction of the CO signal through ROS signalling. Lastly, addition of a chelating agent like 
ethylenediaminetetraacetic acid (EDTA) may mitigate a potential transition metal-dye 
interaction and therefore, reduce the likelihood of a false negative result. 
5.5 oCOm-21 and NO Production Using H2DAF-FM DA 
Very few studies examining the CO-NO axis actually quantified the amount of NO produced. 
Therefore, this study attempted to determine whether CO released by oCOm-21 increased 
intracellular NO levels. The human AC16 cardiomyocyte cell line was chosen for this part of 
the study to provide a proof of concept that oCOm-21 could increase NO in human trabecula 
tissue. Addition of oCOm-21 to AC16 cells at various cell densities along with the spontaneous 
NO releasing molecule, SNP, produced no detectable difference in H2DAF-FM DA 
fluorescence. For SNP to not produce a change in H2DAF-FM DA signal in this study is 
controversial as SNP (1 mM) was found to be a sufficient positive control to induce H2DAF-
FM DA fluorescence over a 5-minute period (Park et al., 2014). The inability to detect a change 
may be due to the formation of cyanide following spontaneous NO release from SNP resulting 
in a decrease in cell viability (Tinker and Michenfelder, 1976). A reduction in cell viability 
would result in the loss adherence of AC16 cells and consequently, a decrease in H2DAF-FM 
DA fluorescence as a bottom read was performed in the present study. However, the inability 
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to detect changes in H2DAF-FM DA fluorescence may be due to the level of endogenous NOS 
expression in AC16 cells. 
Because of the hypothesised signalling pathway where CO released by oCOm-21 activates 
nNOS adjacent to RyR2, confirmation of endogenous nNOS expression within AC16 cells 
needed be performed. This is an accepted limitation in the present study. Findings by Kaczara 
et al. (2018) proved that CO increased NO production in endothelial cells through the pentose 
phosphate pathway. Activation of the pentose phosphate pathway increased the cofactor 
NADPH to increase NOS activity (Kaczara et al., 2018). In cardiomyocytes, the pentose 
phosphate pathway contributes to contractility and the maintenance of the redox state within 
the cell (Jain et al., 2003). However, the contribution of the pentose phosphate pathway in AC16 
cells needs to be determined. In this study, the inability to detect changes in intracellular NO 
with H2DAF-FM DA was proposed to be due to the close proximity between nNOS and RyR2, 
resulting in little NO spill over that was extremely difficult to detect. Therefore, the current 
authors concluded that a more sensitive assay was needed to detect changes in NO due to 
oCOm-21 treatment. This resulted in the pursuit to detect NO with the spin trapping agents 
CPTIO and Fe(DETC)2. 
5.6 Quantification of NO Using Spin Trapping Agents 
To confirm a cardiomyocyte-dependent mechanism of NO generation with oCOm-21, EPR spin 
trapping was implemented. Because of the short half-life of NO, spin trapping agents were used 
to form a spin trap adduct which stabilises the free radical for a sufficient amount of time so 
that it could be detected by EPR spectroscopy. EPR spectroscopy involves determining the 
absorption of electromagnetic radiation of the spin adduct in the presence of an applied external 
magnetic field and microwave radiation. Subsequently, the amount of NO produced can be 
quantified as it is proportional to the intensity of the EPR signal (Kleschyov et al., 2007; Maia 
and Moura, 2016). 
5.7 Spin Trapping with CPTIO 
CPTIO is a water soluble spin trap that produces an EPR absorbance spectrum consisting of 
five lines in the absence of NO binding with a relative intensity of 1: 2: 3: 2: 1. This unique 
spectrum is attributed to the unpaired electrons associated with N2 in the CPTIO complex 
(Kleschyov et al., 2007). Binding between CPTIO and NO occurs in a 1:1 stoichiometric ratio 
(Joseph et al., 1993). Once bound to NO, the amplitude of the signal formed between lines can 
be quantified to determine NO content. The CPTIO formed in this study was found to have a 
minimal detectable sensitivity of roughly 10 μM NO. Stability of the CPTIO-NO complex was 
77 
 
found to degrade over 24-hours, indicating that future experiments involving the CPTIO-NO 
complex needed to be immediately performed. Saturation and degradation of the CPTIO-NO 
signal occurred above 60 μM PAPA NONOate (approximately 60 μM NO), which may be 
attributed to the induction of intracellular antioxidant systems and the potential conversion of 
NO to alternative free radicals such as •NO2 or ONOO
– which are not trapped by CPTIO 
(Akaike and Maeda, 1996; Joseph et al., 1993). Additionally, not all the NO formed within a 
cell is readily available to bind to CPTIO as intracellular components, mainly in the form of 
Fe2+, compete for NO binding (Cooper, 1999). 
Treatment of AC16 cells with oCOm-21 failed to produce a detectable CPTIO-NO signal. 
However, future experiments need to confirm the presence of nNOS in AC16 cells. This could 
be performed by western blotting or through the conversion of radiolabelled L-arginine to  
L-citrulline. Interpretation of these current findings pointed towards the need to use of a more 
sensitive spin trap. This was due to the hypothesised short diffusion distance between nNOS 
and RyR2 and uncertainty with how upregulated NOS activity would be due to oCOm-21 
treatment. Therefore, this resulted in the use of the highly sensitive spin trap Fe(DETC)2. 
5.8 Spin Trapping with Fe(DETC)2 
Fe(DETC)2 is a highly sensitive spin trap for NO. Fe(DETC)2 exhibits a rate constant with NO 
of 108 M/s-1 compared to that of 104 M/s-1 with CPTIO. Fe(DETC)2 binds to NO in a 1: 1 
stoichiometric ratio and produces a triplet EPR spectrum once bound to NO (Kleschyov et al., 
2007; Paschenko et al., 1996; Vanin et al., 2006). In the present study, Fe(DETC)2 was able to 
detect single μM concentrations of NO spontaneously released from PAPA NONOate. 
However, variation in Fe(DETC)2-NO signal and peak amplitude height was high between 
repeats. This was possibly due to precipitation of Fe2+. BSA is known to prevent oxidation and 
precipitation of Fe2+ in mixture with DETC and successful utilisation of BSA with Fe(DETC)2 
had previously been performed by Sheu et al. (2000) and Zhang et al. (2001). Implementation 
of BSA in the present study resulted in a more consistent ability to detect NO as low as 10 μM. 
As previous literature indicated that Fe(DETC)2 could detect pM amounts of NO, further 
optimisation was performed (Kleschyov et al., 2000). Fe(DETC)2 is hydrophobic and water 
insoluble (Zhang et al., 2001). Therefore, an organic solvent, ethyl acetate extraction was 
performed. Implementation of an organic solvent extraction also allows for the concentration 
and hence, amplification of the Fe(DETC)2-NO signal. Consequently, an ethyl acetate 
extraction resulted in an increase in signal amplitude but not an improvement in detectable 
sensitivity below single μM concentrations of NO. Decreasing the temperature also immobilises 
and decreases the thermodynamics of the dissociative reaction to preserve any Fe(DETC)2-NO 
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formed. Reducing the temperature again, increased the magnitude of the observed EPR 
spectrum but not the detectable sensitivity below single μM concentrations of NO. Execution 
of an ethyl acetate extraction prior to the addition of PAPA NONOate (to prevent the diffusion 
of NO out of solution) in combination with measurement of the EPR spectrum at 173 K was 
found to compromise the minimal detectable sensitivity of the assay and hence, was not utilised 
in further studies. In summary, optimisation of the Fe(DETC)2 spin trap in the present study 
resulted in the improvement of the magnitude of the Fe(DETC)2-NO signal but not the 
sensitivity. To determine whether this optimisation was sufficient, the established method to 
record Fe(DETC)2-NO was then performed in cells treated with oCOm-21. 
Addition of oCOm-21 to AC16 cells did not produce a measurable EPR triplet spectrum with 
Fe(DETC)2 at various cell densities. The cell densities of 8.8 x 10
6 and 17.6 x 106 were chosen 
as they were the initial and doubled confluent cell count, respectively. Cells constitutively 
produce NO through eNOS or nNOS and the basal activity of these enzymes is dependent on 
the [Ca2+]i (Förstermann and Sessa, 2012). Increasing the cell count was an attempt to increase 
the absolute concentration of NO to be scavenged by Fe(DETC)2. However, the basal activity 
of eNOS or nNOS in AC16 cells is unclear. The Langendorff and isolated rat cardiomyocyte 
data in the present study suggest a possible positive feedback pathway to modulate nNOS 
activity. The aforementioned data indicates that oCOm-21 altered NO levels to increase 
developed pressure through changes in the [Ca2+]i. Elevation in the [Ca
2+]i may provide an 
additional mechanism to increase nNOS activity which may then go on to upregulate Ca2+ 
release from Ca2+ handling proteins such as RyR2 to subsequently further raise nNOS activity. 
Unfortunately, NO in cells treated with oCOm-21 could not be detected and this may 
inadvertently be due to the cell count. A large cell count results in the downfall of increasing 
non-specific cellular-NO binding which prevents Fe(DETC)2-NO formation. The inability to 
detect the Fe(DETC)2-NO EPR signal in cells may also be attributed to the use of BSA. As 
Fe(DETC)2 is water insoluble, and prepared prior to its addition to cells, it was readily bound 
to BSA (Zhang et al., 2001). Therefore, any NO produced by AC16 cells would have to diffuse 
through cellular components and membranes to reach the extracellular Fe(DETC)2 bound to 
BSA. As NO is known to have a short half-life and be extremely labile, this decreases the 
probability of Fe(DETC)2-NO formation and therefore, its detection (Pacher et al., 2007). For 
the cell suspension to also not produce an EPR triplet structure may further support the 
interpretation that Fe(DETC)2 is extracellular and BSA bound. 
The current Fe(DETC)2 protocol with cells could be improved in many ways. Future 
experiments could omit the use of BSA, instead using cells to prevent Fe2+ precipitation 
79 
 
(Kaczara et al., 2018). This would result in any Fe(DETC)2 formed to be membrane bound 
within cells and be in a closer proximity to the intracellular mechanisms responsible for NO 
generation. Alternatively, investigation of the use of a mild reducing agent like dithioerythritol 
could prevent the oxidation of Fe(DETC)2 which became problematic with increasing time in 
the present study (Paschenko et al., 1996). Lastly, use of a chelating agent like EDTA may 
prevent transition metals, mainly Cu2+, competing with Fe2+ for the DETC ligand. Formation 
of Cu(DETC)2 produces an EPR signal that overlaps that of Fe(DETC)2 resulting in a false 
negative result. (Kleschyov et al., 2007). However, a major short coming involving the direct 
measurement of NO in cells treated with oCOm-21 was the absence of a positive control to 
confirm the viability of the Fe(DETC)2 spin trap formed. 
Implementation of an applicable positive control needed to be performed, either through the 
addition of a NO donor like PAPA NONOate or through the induction of NOS activity. The 
pro-inflammatory cytokine, interleukin-6 (IL-6) has been proven to inhibit cellular contractions 
of chick embryonic ventricular cardiomyocytes within minutes through a NO-dependent 
pathway and this loss of cardiac function was found to be prevented with the NOS inhibitor 
NG-monomethyl-L-arginine (L-NMMA) (Kinugawa et al., 1994). L-NMMA, like L-NAME, 
is a structural analogue of L-arginine and acts as competitive but non-specific inhibitor of all 
NOS isoforms (Vitecek et al., 2012). Alternatively, induction of iNOS expression could be 
performed through the use of IL-6, interleukin-1β and tumour necrosis factor-alpha. These 
inflammatory cytokines all consistently induce iNOS expression over a 24 – 72 hour period in 
cardiomyocytes (Fahmi et al., 2013; Fukuchi et al., 1998; Kacimi et al., 1997; Song et al., 2000; 
Yu et al., 2003). As NOS isoforms share 50 – 60% homology, induction of iNOS followed by 
oCOm-21 treatment would merely be a proof of concept that CO upregulates NOS activity 
within cardiomyocytes (Alderton et al., 2001). Alternatively, if stimulation of endogenous NOS 
activity was not sufficient to produce a detectable NO concentration, attempts to transfect AC16 
cells with nNOS could be performed using the protocol previously described by Eroglu et al. 
(2017) in HEK293 cells to increase basal NO production. 
5.9 oCOm-21 in Human Trabecula 
Use of the trabecula model was extremely novel as it provided a preclinical insight into the 
efficacy of oCOm-21 in diseased myocardium, the eventual demographic that our lab group 
intends to administer oCOms to. Furthermore, this model allowed the determination of whether 
oCOm-21 was having a direct effect in human myocardium in the absence of endothelium. A 
downfall of this model however, was that a homogenous population was not selected. The only 
selection criteria implemented in this study was that patients underwent CABG surgery, atrial 
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valve replacement or a combination of the two. From this selection, characteristics of the 
patients was more heterogeneous in nature i.e. and e.g. patient age, sex, ethnicity and severity 
of ischaemic heart disease was not controlled for. This heterogenecity may explain the 
discrepancy in responses between trabecula due to oCOm-21 infusion. 
oCOm-21 produced an inotropic effect in a unique subset of patients. Notably, trabeculae that 
exhibited an inotropic effect, arbitrarily defined in this study as a 1.1-fold increase in developed 
force from its respective baseline, produced an inconsistent trend with increasing oCOm-21 
concentration. Several trabeculae only produced an increase in developed force at low or high 
concentrations of oCOm-21 while others produced a biphasic concentration-response curve 
similarly seen in isolated rat hearts infused with oCOm-21. This indicates a degree of 
translatability of the oCOm-21 infusion data between rat and human myocardium although 
there are cardiac species differences between the two. Rat hearts exhibit faster action potential 
properties along with quicker contraction and relaxation kinetics than humans to maintain 
cardiac output (Lujan et al., 2012). On a myofilament level, this corresponds to rat myocytes 
expressing more fast twitch, α-myosin heavy chains (MHC) instead of the slow, β-MHCs 
predominantly found in humans (Krenz et al., 2003; Miyata et al., 2000). With heart disease 
progression, a MHC isoform shift takes place to decrease the proportion of α-MHC to β-MHC 
(Krenz and Robbins, 2004; Machackova et al., 2011; Nakao et al., 1997). Therefore, the 
inability to produce a consistent trend in developed force with trabecula infused with  
oCOm-21 may be due to altered myosin kinetics resulting in a decrease in the maximal inotropic 
response. 
Remaining trabecula that did not exhibit an inotropic response to oCOm-21 instead, produced 
a concentration-dependent decrease in developed force. This decrease in developed force was 
a major concern in the present study and may be due to several variables. As trabecula were 
exposed to multiple concentrations of oCOm-21 and subsequent wash phases until a 
concentration-response curve was achieved, the decrease in developed force may be due to a 
decrease in viability with progressing time. The reduction in the developed force may also be a 
drug-dependent effect. CO is known to inhibit complex IV of the mitochondrial respiratory 
chain to decrease ATP resulting in reduced cross-bridge cycling efficiency (Lo Iacono et al., 
2011; Tewari et al., 2016). Binding of CO to complex IV may persist through the multiple wash 
phases and escalating oCOm-21 concentrations. Therefore, future studies should implement 
infusing only a single concentration of oCOm-21 to mitigate the variable of decreasing viability 
with increasing time. Additionally, a method of determining the maximal developed force of 
the exposed trabecula following oCOm-21 infusion should be performed to confirm viability. 
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This could be achieved by adding a β-agonist or simulating SOICR by pausing electrical 
stimulation at the end of the oCOm-21 infusion protocol. However, this suffers from the 
confounding factor that these means of maximal force determination are performed in the 
presence of oCOm-21 and whether oCOm-21 potentiates or antagonises these effects are yet to 
be determined in human cardiac tissue. Alternatively, a time-control could be implemented 
where trabecula originating from the same patient were not perfused with oCOm-21 to indicate 
the degree of developed force decay over time. It could be that although oCOm-21 did not 
produce an inotropic effect, oCOm-21 preserved myocardial function over time compared to 
those not infused with oCOm-21. 
oCOm-21 produced variable changes in developed force which may be due to structural 
alterations within trabeculae. In the present study, CSA was calculated from live preparations 
and the force generated by the trabecula was adjusted to its CSA. This was because previous 
literature indicated that the developed force was correlated with the CSA of the muscle (Bruce 
et al., 1997). This normalisation takes place to allow for the comparison of developed force 
from trabecula between different hearts/patients. The current study found that the CSA of 
responding and non-responding trabeculae to oCOm-21 did not influence the observed 
concentration-dependent divergence within haemodynamic parameters. However, future 
studies should determine CSA by transverse sections of the tissue following fixation. This 
prevents optical and/or tissue orientation from influencing radius measurements – especially 
when the trabecula is more elliptical in nature. More importantly, Munro et al. (2018) brought 
to light that the standard measurement of CSA (as performed in this study) was an inaccurate 
method to adjust developed force by in diseased myocardium. This was because tissue 
composition within, and developed force between trabecula originating from the same heart 
was found to be extremely variable. Examination of the transverse CSA determined that 
cardiomyocyte area (CCSA), and not total CSA, was more strongly correlated with developed 
force. The remaining area (i.e. CSA minus CCSA) was found to be the extracellular matrix in 
the form of collagen I, III and VI, indicating cardiac fibrosis and this too, was highly variable 
between trabecula (Munro et al., 2018). Fibrosis occurs in the myocardium to replace the loss 
of cardiomyocytes and results in myocardial stiffness that opposes force generation. With this 
resistance to force development, cardiomyocytes are required to generate more active force to 
create the necessary myocyte shortening needed (Vahl et al., 1993; Weber et al., 1989). 
Trabecula that failed to produce a concentration-dependent increase in developed force may 
present with a higher degree of cardiac fibrosis. It may also be that the cardiomyocytes within 
these non-responsive trabeculae were already functioning at a maximal capacity to achieve 
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sufficient active force development that, no further contractile reserve was present to produce 
an inotropic effect. In combination with CO which is known to increase myocardial O2 demand, 
this may explain the observed decrease in developed force overtime (Wang et al., 2014). 
Collectively, this may therefore, inaccurately represent oCOm-21’s ability to induce an 
inotropic effect. Follow up studies should confirm the degree of cardiac fibrosis and correlate 
CCSA with developed force. In the present study, although CSA was not different between 
responders and non-responders, the discrepancy between the two groups with regards to 
developed force in response to oCOm-21 may be due to fibrosis, as indicated by differences in 
LVPWd from the patient echocardiographic data. 
Use of atrial trabeculae may not be the most accurate model to represent the inotropic effects 
of oCOm-21 in the whole heart. In particular, there are differences between atrial and 
ventricular myocytes in transmembrane ion channel expression and SR structure that reflect 
their specific roles during a cardiac contraction (Barton et al., 2015). Atrial myocytes are unique 
compared to their ventricular counterparts by: 1) lacking transverse tubules (T-tubules) which 
situate the LTCC in close proximity with RyR2 for CICR and 2) by having significantly 
upregulated mitochondrial Ca2+ uptake and SERCA expression resulting in vastly different Ca2+ 
release and propagation patterns in response to excitation (Bootman et al., 2011; Lüss et al., 
1999; Mackenzie et al., 2004). In a single atrial cardiomyocyte, depolarisation results in Ca2+ 
release from the periphery of the myocyte. This Ca2+ does not propagate inwards towards the 
core of the cell as increased mitochondrial Ca2+ uptake and SERCA expression lower the 
systolic Ca2+ transient (Lüss et al., 1999; Mackenzie et al., 2001; Mackenzie et al., 2004; 
Walden et al., 2009). Consequently, this does not result in full actin-myosin cross-bridge 
cycling recruitment (Bootman et al., 2011). The reduction in T-tubules was also correlated with 
RyR2 clusters only being present around the periphery of atrial cells (Carl et al., 1995; Hatem 
et al., 1997). In disease states such as heart failure, T-tubule density is decreased and more 
irregular with an increased number of tubules in the longitudinal than transverse plane (Lyon 
et al., 2009; Song et al., 2006; Wei et al., 2010). Disruption in T-tubule structure results in 
altered (dyadic) distance between LTCC and RyR2 leading to desynchronised CICR and a 
reduced force of contraction (Gomez et al., 1997; Ibrahim et al., 2012). Therefore, testing 
oCOm-21 in diseased atrial tissue may mask its true inotropic response due to the increased 
dyadic distance and the natural propensity of atrial tissue to sequester and expel Ca2+ to reduce 
the systolic Ca2+ transient. This may be further potentiated with cardiac fibrosis where trabecula 
exhibit reduced drug uptake due to the increased presence of collagen and the lower number of 
effective myocytes through which oCOm-21 can act upon. Therefore, the use of diseased 
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ventricular trabeculae may provide a more clinically relevant insight into the effectiveness of 
oCOm-21 as an inotropic agent in human myocardium. In the present study, it is evident that 
the disease state that the trabecula presented with also influenced the inotropic response due to 
oCOm-21 infusion. 
This study found that the patient characteristics of trabecula that exhibited an inotropic effect 
with oCOm-21 had significantly increased body weight and body surface area. Although body 
mass index (BMI), a measure to gauge weight status and disease risk, was not found to be 
significantly different between the responders and non-responders to oCOm-21 (p = 0.15, 
Appendix 2); body weight in combination with body surface area and BMI raised the potential 
influence of the “obesity paradox” in the present study. Patients with a high BMI and defined 
as overweight or obese with chronic heart failure have been found to have a reduced stroke risk 
and mortality rate compared to those with a BMI defined as recommended or underweight 
(Calle et al., 1999; Horwich et al., 2001; Wassertheil-Smoller et al., 2000). This may be 
explained by overweight and obese patients being diagnosed at an earlier stage of heart failure 
than patients with a lower BMI due to an increased cardiac output and myocardial demand 
(Abbasi et al., 2002; Curtis et al., 2005). Therefore, in the current study, more overweight and 
obese patients may present with less severe myocardial dysfunction and be more inclined to 
respond to oCOm-21 than those with a lower body weight. Additionally, patients with 
progressively worsening heart failure are known to lose body weight over time and are 
associated with cardiac cachexia (a weakness and wasting away due to illness) (Anker and 
Sharma, 2002). Cardiac cachexia is linked to poor cardiac performance and may also explain 
the discrepancy between the responding and non-responding group exhibiting an inotropic 
effect with oCOm-21. This reduction in myocardial dysfunction in the responding group may 
be reflected by a lower LVPWd (an indicator of cardiac fibrosis) but increased right atrial area 
and inherently, increased the right atrial end systolic volume compared to the non-responding 
group. 
The difference between responders and non-responders to oCOm-21 may also be due to the 
oxidative stress present in the experimental trabecula tissue. With the progression of IHD, a 
myocardial redox imbalance takes place which influences Ca2+ handling proteins (Choudhary 
and Dudley, 2002). RyR2 is extremely susceptible to reversible S-nitrosylation though this is 
superseded by irreversible oxidation (Ather et al., 2013). Oxidation of RyR2 results in abnormal 
SR Ca2+ release and a biphasic increase in channel open probability, where excessive oxidation 
results in RyR2 channel closure (Xie and Zhu, 2006; Yan et al., 2008). Experimental models 
examining the gating properties of RyR2 suggest that chronic ROS exposure increases the 
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release threshold for SOICR, preventing further SOICR events and RyR2 opening (Waddell et 
al., 2016). Mechanistically, this is due to oxidation forming crosslinking disulphide bonds 
within RyR2; though whether this is dependent on thiol groups that are within the channel pore, 
on the transmembrane domain or between RyR2 subunits needs to be determined (Aghdasi et 
al., 1997; Eager and Dulhunty, 1999). Therefore, if oCOm-21 upregulates O2
•– through complex 
IV inhibition and/or acts as a S-nitrosylating agent through nNOS; the potential for further 
irreversible modulation of RyR2 can take place which may explain the observed decrease in 
developed force with increasing concentration of oCOm-21 in numerous trabeculae within this 
study. 
The initial redox state within trabecula may explain the observed differences in response to 
oCOm-21. Trabecula presenting with a neutral redox state may of have had exhibited a more 
positive or biphasic correlation in developed force when infused with oCOm-21. However, with 
a high initial oxidative stress, non-responding trabeculae to oCOm-21 produced a 
concentration-dependent decrease in developed force, dF/dTmax
 and dF/dTmin. Due to the wide 
sources of ROS involved in the pathogenesis of IHD (NADPH oxidase, xanthine oxidase, 
lypoxidase and myeloperoxidases), evaluation of the current redox balance within trabecula 
should be determined. This could be achieved by: 1) the direct measurement of O2
•– levels 
through the dihydroethidium (DHE) assay which fluoresces when oxidised by O2
•–; 2) 
quantification of antioxidant capacity present within trabecula through SOD or GSH 
activity/abundance and 3) in the interest of the oCOm-21 S-nitrosylating RyR2, the extent of 
oxidative protein damage present using the 2,4-dinitrophenylhydrazine (DNPH) method which 
measures the upregulation of carbonyl modified amino acids during oxidative stress (Benov et 
al., 1998; Cervantes Gracia et al., 2017; Halliwell and Gutteridge, 1986; Levine et al., 1990; 
Lu, 2009). Determination of protein oxidation would be of particular interest to understand the 
further susceptibility of Ca2+ handling proteins to additional oxidation/post-translational 
modifications which could be induced by oCOm-21. Furthermore, by performing such 
protocols, this would provide an insight into whether the effectiveness of oCOm-21 as an 




5.10 Clinical Relevance  
Positive inotropic agents are used to achieve adequate haemodynamic status and improve 
systemic end organ perfusion in patients undergoing cardiac or vascular surgeries (Fellahi et 
al., 2013). As a large proportion of these patients are on β-blockers, use of a β-independent 
inotrope has been explored to rectify low cardiac output syndrome. Current inotropic agents 
have consistently failed to show any benefit beyond the perioperative setting in acute heart 
failure (Hasenfuss and Teerlink, 2011). Agents such as milrinone, a phosphodiesterase III 
inhibitor, significantly increased the incidence of hypotension and arrhythmia in patients 
presenting with systolic chronic heart failure (Cuffe et al., 2002). Furthermore, milrinone has 
been proven to increase in-hospital mortality and mortality rate in patients undergoing cardiac 
surgery (Abraham et al., 2005; Zangrillo et al., 2012). Therefore, this failure highlights the 
clinical need for a positive inotrope that not only improves short-term haemodynamic 
parameters but also postoperative outcomes. Evaluation of current positive inotropes in clinical 
practice by Fellahi et al. (2013) generated a theoretical criteria for the ideal inotrope in cardiac 
surgery. The use of CO released by oCOm-21 may provide distinct advantages over other 
inotropic agents in an operative setting by being an inodilator (with both positive inotropic and 
vasodilatory properties) that is β-independent and easily titrated. The present study suggests 
little to no arrhythmogenesis following oCOm-21 administration. Furthermore, CO is a known 
preconditioning agent with anti-apoptotic and anti-inflammatory effects associated with the 
preservation of cardiac function in experimental models of I/R injury (Fujimoto et al., 2004; 
Guo et al., 2004). This claim is supported by previous work from this lab group where oCOm-
21 was an effective preconditioning agent in both normal and hypertensive hearts (Adams et 
al., 2017; Chau et al., 2018). Therefore, to verify the effectiveness of oCOm-21 in a clinical 






CO released by oCOm-21, the active CO releasing compound, was shown to produce an 
inotropic effect. The mechanism of CO-induced inotropy was proven to be NOS-dependent in 
the rat heart. To determine the mechanism of inotropy, changes in [Ca2+]i due to oCOm-21 
infusion were investigated. oCOm-21 (1 µM) increased [Ca2+]i in isolated rat cardiomyocytes 
however, oCOm-21 did not change the incidence of SOICR events experienced in 
RyR2/HEK293 cells; indicating no change in the RyR2 (and SERCA) gating activity. This lack 
of change in RyR2 gating was supported by the fact that oCOm-21 infusion did not result in SR 
Ca2+ leak as the number of spontaneous contractions did not change with increasing oCOm-21 
concentration in isolated rat cardiomyocytes. Examination of the cellular mechanism of 
inotropy evoked by oCOm-21 was found to be dependent on basal ROS production though 
whether NO was upregulated could not be determined in the present study. Quantification of S-
nitrosylation through western blotting using a commercially sourced antibody was unsuccessful 
and also needs further confirmation. 
To date, this is the first known confirmation of the inotropic action of CO at low concentrations 
in human myocardium. The present study confirmed that oCOm-21 was a positive inotrope 
within a unique subset of diseased human myocardium originating from hearts with reduced 
LVPWd but increased right atrial area and right atrial end systolic volume. Surprisingly, the 
trabeculae that exhibited an inotropic effect originated from patients with a larger body weight 
and body surface area which may be attributed to the “obesity paradox.” Future studies need to 
confirm whether CO/oCOm-21 can directly upregulate NO, protect myocardial tissue against 
I/R injury through the novel mechanism of S-nitrosylation via NOS and whether this 
mechanism of cardioprotection translates into a more clinically relevant setting such as cardiac 
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Appendix 1. Representative western blots for RyR2, general S-nitrosylation and β-tubulin. 
Following isolated Langendorff rat heart perfusion, hearts were snap frozen, homogenised and 
processed for western blotting for A) RyR2 and B) SNO with the corresponding β-tubulin blots 
C) and D), respectively. Lanes are indicated as the protein ladder or total amount of protein 
loaded from either untreated rat or GSNO (1.6 mM) mice heart treated tissue where appropriate 






















































































































































































































Appendix 2. Body mass index between responders and non-responders. Atrial trabecula and 
subsequent associated BMI was separated into responders (●, n = 8) and non-responders  
(■, n = 11) based on whether an inotropic effect was observed with oCOm-21 (0.1 – 10 μM) 
treatment. Bars represent mean ± SEM and data was analysed using a non-parametic Mann-
Whitney t-test. 
